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Summary
Excipients are indispensable functional components, which are used to develop innovative, robust,
and reproducible formulations with good patient compliance due to optimized plasma concentra-
tions and less side effects. Nowadays, new excipients have to show a multifunctionality in order to
be used for unique applications that are not feasible with existing excipients. This multifunction-
ality can be achieved by co-processing excipients, where undesirable properties of an excipient are
masked, favorable attributes are retained, and new properties supplement the substance.
The main aim of this thesis was to map the applicability of such a co-processed novel excipient,
FCC, in the field of pharmaceutical technology.
The results of the mechanistic study showed that the attributes of FCC present a striking success
in the field of excipient research. FCC-based tablet formulations had mechanical properties equal
or superior to those of conventionally used excipients such as microcrystalline cellulose (MCC),
mannitol, or calcium carbonate. FCC tablets with high tensile strength and high porosity were
obtained already at low compressive pressures. The key factor for the outstanding performance
of FCC was the lamellar structure of the particle, which formed a porous meshwork (intraparticle
porosity), resulting in a high specific surface area available for particle bonding.
The limitations of poor flowability and high bulk density of FCC powder during direct compression
were overcome by granulation. FCC granules prepared by roller compaction showed excellent
flowability and reduced bulk volume, whereas all the outstanding properties of the powder, such as
compactability and compressibility, were preserved. The dry granulation process converted FCC
into a suitable form for scale-up processes on high-throughput tablet presses. Roller compaction is
the process of choice if porosity and high surface area of FCC particles have to be preserved during
granulation process.
On the examplary model of direct compressed ODTs, the applicability of FCC was investigated.
ODTs containing FCC were produced by direct compression. Owing to the lamellar structure, FCC
was able to overcome the limitation of insufficient hardness during the production of highly porous
ODTs. These findings could revolutionize the production of ODTs and hence open up new vistas.
To protect the valuable findings, a patent was applied for the production of ODTs made of FCC.
The characterization of co-processed FCC revealed a promising new pharmaceutical excipient with a
broad range of applicability. Applicability of FCC seems to be of particular interest for formulations
that are characterized by high porosity, high tensile strength, or both. This is the case, amongst
others, for ODTs, carriers, adsorbents, floating tablets, effervescent tablets, controlled-released
formulations, ultra hard tablet (UHT), and cushioning agents.
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Chapter 1
Introduction
1.1 Pharmaceutical excipients
Excipients were already used in the ancient Greece to produce salves and ointments made of natural
materials [1]. The function of the excipients was to convert the active pharmaceutical ingredient
(API) in a form that was convenient for the patient [2]. That time, people did not pay a lot of
attention to the excipients and considered them as inert. A turning point came in the year 1937.
A chemist decided to mix the toxicologically untested excipient diethylene glycol with sulfonamide
antibiotics that had a bad taste. The result was a blue colored elixir with a sweet taste. After
taking this elixir, over 100 children died and several hundreds became ill. The reason was the
toxicity of the excipient, leading to kidney failure. As a consequence, a law was enacted in 1938
that regulates the responsibility of the manufacturer for drug safety [3–5].
The situation has changed again since 1970. New technologies enabled the investigation of excipients
with respect to solid state of materials. Therefore, regulatory authorities increased qualitative
requirements. Amongst others, this led to to the International Conference on Harmonization where
people from the United States, Japan, and Europe worked on a harmonization of the standards [6].
Furthermore, the first edition of the reference book "Handbook of Pharmaceutical Excipients" was
published in 1986 [7].
1.1.1 Definitions
Different definitions exist for the word excipient, depending on the source. The International
Pharmaceutical Excipients Council (IPEC) for example defines excipient as follows [8]:
"Pharmaceutical excipients are substances other than the API which have been appro-
priately evaluated for safety and are intentionally included in a drug delivery system."
In contrast, the definition of the European Pharmacopeia (PhEur) is shorter but contains some
examples [9]:
"Excipient (auxiliary substance): Any constituent of a medicinal product that is not an
active substance. Adjuvants, stabilizers, antimicrobial preservatives, diluents, antioxi-
dants, for example, are excipients."
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The PhEur does neither mention anything about safety of the excipient, nor about the intentionally
addition of it into the formulation. The latter could imply that contaminations and impurities are
defined as excipients [10].
1.1.2 Function of excipients
As mentioned above, in the past excipients were considered as inert. Nowadays, excipients are
treated as functional components of the formulations [6,11]. In the following sections, a selection of
functions are presented to give an overview over the broad field of application of excipients. From
now on the focus is on the use of excipients for tablet formulations.
Dosing: Some APIs, such as paracetamol, are taken in amounts up to 1 gram per dose. In contrast,
there are active substances such as digoxin that are taken in very small amounts of 0.125 mg per
dose [12]. Excipients allow to compact tablets with convenient sizes and shapes, regardless of the
API content. The tablet press enables a consistent volumetric dosing of the required amount of
powder used for one tablet [1].
Palatability: The success of a formulation on the market depends strongly on the palatability of a
formulation. Taste, smell, and swallowability are parameters that influence the palatability. Ex-
cipients serve, for example, to mask a bitter tasting API or to disintegrate a tablet already in the
mouth to reduce swallowing problems [1, 6, 13].
Controlled release: Excipients are used to control the release of a dosage form. Different excipients
cover the whole spectra; from very fast dispersible tablets (drug release in the range of seconds)
to sustained release formulations (drug release over several hours) [14, 15]. The release pattern
determines the frequency of dosing and thus influences patient compliance.
Stability: Stability of APIs is an important prerequisite to achieve the expected plasma concen-
trations. Excipients can, for example, help to hold up the desired polymorphic form of the API.
Another example is the protection of acidic degradation of an API in the stomach with an enteric
coating [16].
Bioavailability: Oral administration of drugs is by far the most widely used route of administration.
However, some drugs such as peptides and proteins, still need to be administered by the parenteral
route. These drugs are limited by low bioavailability, for example due to presystemic enzymatic
degradation, and poor permeability through the intestinal membrane [17].
Drugs can be classified according to the biopharmaceutical classification system (BCS) as shown in
Figure 1.1. The system divides the APIs into 4 classes according to low or high solubility and low
or high permeability [18]. APIs which belong to the BCS class I possess all the prerequisites for
a high bioavailability, namely high solubility and high permeability. All the other APIs from BCS
classes II-IV have either low permeability, low solubility, or both, resulting in reduced bioavailabil-
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ity. Excipients can help to overcome these limitations and to make these challenging APIs available
for oral administration. Numerous excipients are used to increase the solubility of APIs, such as
polyethylene glycol, cyclodextrin, and glycerin [19]. In order to overcome the limitation of low
permeability, innovative delivery systems are needed. Such an innovative approach is for example
the chitosan nanoparticle-mediated oral delivery of insulin [17,20].
Beside the fact that excipients can be used to overcome the limitation of low solubility and low
permeability, they can also have an influence on the gastrointestinal motility themselves. Excipi-
ents, such as mannitol and other sugar alcohols, are often used to sweeten a formulation or as a
diluent. Sugar alcohols can reduce the transition time of a formulation in the gastrointestinal tract
and hence, reduce the bioavailability of BCS class III drugs with high solubility and low perme-
ability [16].
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Figure 1.1: BCS of APIs based on their solubility and permeability. APIs in BCS class I show
the prerequisites for high bioavailability. Bioavailability of APIs in BCS class II and III is either
affected by low solubility or low permeability. APIs in BCS class IV show lowest bioavailability
due to low solubility and low permeability [18].
Side effects: A selective use of excipients can improve a certain release profile that peaks in the
plasma can be avoided and thus, side effects are reduced [1].
To sum up, excipients help to develop innovative, robust, and reproducible formulations with good
patient compliance due to optimized plasma concentrations and less side effects.
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1.1.3 Categorization of excipients
Three different types of excipients are discriminated, namely standard excipients, mixed excipients
and co-processed excipients. In the following sections, the three different types are presented and
illustrated with some examples [8].
Standard excipients
Standard excipients are substances, that neither belong to the mixed excipients, nor to the co-
processed excipients. Standard excipients can be compendial or non-compendial. Beside the sub-
stance itself, residual processing aids or additives and concomitant components can coexist [8].
Examples for standard excipients are microcrystalline cellulose, UICEL, and crospovidone, which
are presented now more detailed.
MCC (e.g. MCC Sanaq R©, Avicel R© PH, Vivapur R©): Cellulose is the fibrous material of plants. Cel-
lulose shows an amorphous and a crystalline part. The latter consists of two polymorphic forms,
cellulose I and cellulose II [7]. To extract MCC out of cellulose, the cellulose has to undergo a
hydrolysis with a strong mineral acid in form of an aqueous solution. Afterwards, the product is
filtrated to purify it and the aqueous slurry is spray dried. The result is MCC as porous particles
with different particle sizes, depending on the grade [21]. MCC shows the polymorphic form of
cellulose I, which corresponds to the native cellulose lattice. Within the cellulose I form, a parallel
arrangement of the chains is observed. This results in a higher degree of crystallinity compared to
the cellulose II form [22]. The degree of crystallinity is important due to the fact that properties
such as compactability and flowability are affected [6]. MCC is used as a binder and diluent for
direct compression as well as for wet granulation [7]. MCC is a popular excipient, especially due
to the fact that it shows excellent compactability and compressibility. Nevertheless, flowability of
MCC is only moderate [23,24].
UICEL (e.g. MCC Sanaq R© burst): The name UICEL is the abbreviation of University of Iowa
Cellulose. At this university, the substance was produced and investigated for the first time. The
basic raw material for this excipient is the same as for MCC, namely cellulose. To obtain UICEL,
the cellulose goes through a mercerization process, where it is soaked in a sodium hydroxide solu-
tion. Afterwards, it is precipitated with ethyl alcohol and subsequently neutralized with water. In
a last process step, the powder is dried. In contrast to MCC, UICEL consists of the polymorphic
form of cellulose II. This results in properties that make UICEL an effective disintegrant. In ad-
dition, the excipient is still a good filler and binder. The better taste compared to other cellulose
types in combination with good binding and disintegration properties make the UICEL a promising
excipient to produce orally dispersible tablets [21,25].
Crospovidone (e.g. Kollidon R© CL): Crospovidone is produced over several chemical reaction steps
out of acetylene and formaldehyde. Among other things, crospovidone is used as a tablet disinte-
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grant in the concentration of 2-5%. The function of crospovidone as a disintegrant bases upon the
high capillary activity and hydration capacity [7].
Mixed excipients
Mixed excipients are two or more standard excipients that are physically mixed for a short duration
by a low- to medium-shear process. During this process, the substances are not allowed to change
chemically. Examples for mixed excipients are flavor and color blends [3, 7].
Co-processed excipients
Co-processed excipients are two or more standard excipients, whose properties are physically mod-
ified without changing the chemical properties significantly. The same result cannot be achieved
by a physical mixture of the substances [8]. Particle engineering plays an important role in co-
processing of excipients. In general, solid substances consist of three levels, namely a molecular
level, a particle level, and a bulk level. These three levels are connected and a change on one level
does influence the other levels. On the molecular level, the arrangement of the molecules in the
crystal lattice is regulated and does therefore give information about polymorphism and amorphous
state of a substance. The particle level determines the properties of the individual particles, such
as size, surface area, shape, and porosity. The bulk level reflects the interaction of the particles
that can be measured with the help of flowability, compressibility, and dilution potential.
During the co-processing step, one excipient is incorporated into the particle structure of another
excipient. The processes used are for example spray drying, melt extrusion, or high shear gran-
ulation. With this procedure, a multifunctionality can be achieved by masking the undesirable
properties of an excipient, retaining the favorable attributes, and supplementing a substance with
new properties.
It seems that co-processed excipients are the excipients of the future due to the fact that they can
be used for unique applications that are not feasible with existing excipients due to problems with
performance or consistency. Furthermore, co-processed excipients can be produced by meeting the
needs of quality by design [3, 9, 26]. What quality by design is, will be discussed later on. In the
following sections, two examples of co-processed excipients are shown.
Silicified microcrystalline cellulose (SMCC)(ProSolv R© SMCC): SMCC consists of MCC and 2%
(w/w) of colloidal silicon dioxide. It is obtained out of a suspension of MCC and colloidal silicon
dioxide that is co-dried. The colloidal silicon dioxide binds physically on the surface and inside the
SMCC particles. SMCC is used as a diluent in tablet production. The co-processing of the two
excipients yielded in improved flow properties of SMCC compared to MCC. Furthermore, SMCC
showed improved compaction properties in direct compression, as well as after wet granulation
compared to MCC [7,24,27,28].
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Ludipress R©: Ludipress R© is a combination of 93% lactose monohydrate (filler), 3.5% polyvinylpyrroli-
done (binder), and 3.5% crospovidone (disintegrant). Lactose monohydrate is a natural disaccharide
that is obtained from milk. Polyvinylpyrrolidone and crospovidone are both obtained with chem-
ical reactions out of acetylene and formaldehyde. The excipient Ludipress R© is produced with the
help of a fluidized bed process. Ludipress R© shows added advantages such as excellent flowabil-
ity due to sphericity and smooth surface of particles. Furthermore, the hygroscopicity is lower.
Beside the improved properties in comparison to lactose monohydrate, there is still a need for a
glidant [7, 29–31].
1.1.4 Need for new excipients
Even nowadays there are manifold reasons for new excipients. One reason are new technologies that
allow tablet production with high-speed tablet presses. Such machines can produce up to 1.5-2.0
millions of tablets per hour. The powder has to meet a lot of requirements to be compacted with
such a press, such as good flowability, good compressibility, and low moisture sensitivity. There is a
demand for a binder that fulfills all these criteria. [3,29]. Another reason is the need for excipients
to formulate new, innovative APIs, such as peptides. In general, there is a need for elaborated
excipients that can be used for modified release formulations and new therapeutic systems [6]. The
problems with low solubility and low permeability (BCS class II-IV) represent an omnipresent need
for new excipients [3].
The possibility to engineer particles on request by co-processing two or more existing excipients or
to develop a new chemical entity leads to the question how an ideal excipient is defined. In the first
instance, this clearly depends on the tablet formulation that should be designed. The following
points should be kept in mind by working on an ideal excipient [6]:
• Toxicologically and pharmacologically inactive
• Physically and chemically inert versus the drug
• Compatible with other formulation components
• Good flowability
• High compressibility
• Inexpensive
• Worldwide available from different suppliers
• Reproducible to minimize batch to batch variability
• Well characterized
The itemization discloses that it is challenging to work on a novel excipient that can fulfill all these
requirements.
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1.2 Further processing of excipients
The easiest way to produce a tablet out of an API and excipients is the direct compression. To do so,
the powder blend has to meet some requirements. If the requirements are not met, another process
step has to be included, namely the granulation. Granulation can be split into wet granulation and
dry granulation. Before 1950, tablets were mainly produced by wet granulation. Nowadays there
is a clear trend towards direct compression of tablets. The development of new and co-processed
excipients as well as advanced tablet presses may be responsible for this trend due to the fact that
more excipients can fulfill the requirements for direct compression [23, 29]. Due to the fact that
a lot of new APIs are chemically sensitive, there is another trend from wet granulation to dry
granulation. The liquid and the heat during the drying process after wet granulation stress the
fragile APIs. Moreover, a lot of new APIs have a low bulk density that can be increased more
effective by dry granulation than by wet granulation [32].
1.2.1 Direct compression
Direct compression is featured by advantages. It is a short and effective process that is at the
same time cost efficient. The API and the excipient have simply to be blended and compacted.
Furthermore, the process is suitable for heat- and moisture sensitive APIs [33]. Nevertheless, there
are some issues that limit the application range of direct compression. Formulations with very high
or very low API content are challenging for direct compression [33, 34]. For formulations with a
low API content, a homogeneous distribution of the drug in the powder blend has to be ensured.
Segregation, for example, is a problem that can occur due to differences in particle sizes, densities,
and flow properties [35]. Static charges are another problem and may lead to a powder blend with
nonuniform API distribution [36]. All these problems lead finally to a nonuniform distribution of
the API in the tablet formulation. Another problem is observed if the API doses are very high; the
low amount of excipients is not able anymore to compensate the poor compressibility of the API,
resulting in a bad tablet quality [33, 34]. Furthermore, the raw materials should be characterized
by a good flowability. A good flowability is indispensable to receive a consistent tablet weight, and
hence a uniform distribution of the API in the tablet [37]. Another limitation for direct compression
is a low bulk density of the powder. In this case the required volume of powder to produce a tablet
with a certain amount of API can be higher than the volume of the die, or the resulting tablet is
very thin [34,38].
Different types of excipients can be used for direct compression, including lubricants, disintegrants,
binders, and fillers. The binder holds everything together within a tablet and therefore plays an
important role during direct compaction. The binder, as well as the filler (especially if used in
large amounts), is ideally characterized by a good flowability and compactibility. The excipients
have to be chosen carefully by considering the properties of the API, such as particle size, shape,
9
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brittleness, and elasticity [38].
1.2.2 Granulation
If raw materials are limited by above mentioned issues, they have to be granulated. Due to an
additional process step, the production of the formulation needs more time and more costs incur.
Furthermore, there is a loss of product due to the fact that the granulation process consists of
several steps; granulation, drying, milling, and sieving [33].
The granulation serves to produce powders with a desired flowability (enlargement and densification
of small powder particles) and reduces the amount of dust. Furthermore, powders with a narrow
particle size distribution are produced to overcome the problem of segregation during tableting
[33,39].
If the amount of API in a formulation is very high, the API can be granulated alone and later on
added to the powder blend with the excipients. In case of a low API content it makes more sense
to granulate the API together with the excipients to reduce the risk of segregation. Nevertheless,
the procedure has to be evaluated for each formulation separately by considering the properties of
the raw materials [33,34].
Dry granulation
Dry granulation is sub-divided into slugging and roller compaction. By slugging, the powder is
compacted with the help of a compression machine into a slug, similar to a large tablet. Nowadays,
slugging is replaced by roller compaction. Reasons for the substitution of slugging by roller com-
paction were the low throughput per hour, poor process control and that it was not a continuous
process [39].
The roller compaction process has the advantage that heat- and moisture sensitive drugs can be
processed with this method [40]. Even poor flowing raw materials are suitable for roller compaction
due to a feeding system that brings the powder to the rolls [41]. A disadvantage of the dry gran-
ulation process is the loss of reworkability, meaning that tensile strength of the tablet is reduced
after compacting the granules in a tablet in comparison to powder. In general, plastic deforming
materials are more affected by the problem of reworkability [42,43]. Another negative issue during
roller compaction is the production of fines. A study showed that this problem can be controlled
with different roll surfaces (e.g. convex instead of smooth) [44]. Numerous studies were performed
in the past to show the influence of roll speed, roll pressure, and feeding screw speed on the granule
properties and consequently on the tablet properties [45–48].
By selecting suitable excipients during roller compaction the processibility of a powder mixture can
be improved by balancing the poor physical properties of the API. Similar to direct compression,
binders and fillers belong to the most important excipients used for roller compaction. Fillers are
responsible for good ribbon and granule quality by balancing the plasticity/elasticity/brittleness
10
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of the API. Binders play an important role during the agglomeration process of the API and the
excipients. Polyvinylpyrrolidone and cellulose derivatives are examples for binders commonly used
for dry granulation [49].
Wet granulation
Wet granulation was, and most probably still is, the most common way of granulation. Different
types of wet granulation exist, namely fluidized-bed granulation and high-shear granulation. The
process is chosen depending on the required properties of the granules. Fluid-bed granulation is
a low-shear process where granules with a low density are obtained. The high-shear granulation
results in denser granules due to the fact that more shear (mechanical force) is applied [34].
During the wet granulation process, a solution (either aqueous or solvent based) is pumped into the
machine. In most of the cases, a binder that later on forms the powder agglomerates (granules),is
dissolved in the solution. The wet granulation process is a critical unit operation at which the
particle size distribution during granulation is depending on the liquid addition. Since years,
researchers are looking for the end-point during wet granulation. The power consumption profile
during a wet granulation can be divided into different phases, however, there is no clear scientific
end-point [50,51].
After the granulation process, the granules have to be dried. This process is critical in view of the
fact that the moisture content of the granules has an impact on the compaction behavior of the
granules. Overdried granules result in a high fine fraction after milling, which in turn is responsible
for weight variations due to bad flowability. Furthermore, overdried particles can cause capping
and lamination. On the other side, if the granules are too wet during tableting, the powder can
stick on the tooling [34].
1.3 Quality by Design
Four different components play an important role during the pharmaceutical development, namely
the API, the excipient(s), the process, and the interaction of these three components [1]. It is obvi-
ous, that these components are decisive responsible for product quality. In 1992, Juran published
a book where he presented his idea of Quality by Design (QbD). He was of the mind that the
quality is projectable [52]. Some years later, the Food and Drug Administration (FDA) introduced
a guidance for the industry due to the fact that they noticed that, although a lot of tests were
performed, the quality did not improve. Therefore, they suggested that "quality should be built in
by design" [53].
In general, QbD means for the pharmaceutical development industry that they understand their
products and the processes involved to obtain a certain product. The FDA recommends to consider
at least the subsequent mentioned points.
11
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In a first step during pharmaceutical development, the quality target product profile (QTPP) has
to be defined. The quality, safety, and efficacy are in the spotlight of QTPP. Related questions
to be answered can for example concern the intended use, dosage form, dosage strength, and the
drug release out of the dosage form. In a next step, potential critical quality attribute (CQA) of
the drug product have to be pinpointed. This allows later on a study and control of product char-
acteristics that impacted the quality of the product. The CQAs have to be within a defined limit
that they can meet the pre-estimated QTPP. According to the desired quality, the drug substance
and excipients are selected based on their CQAs. The drug product is afterwards produced with an
adequate manufacturing process. The critical process parameter (CPP) such as for example mixing
speed or temperature are measured. Finally, the FDA recommends an appropriate control strategy
to measure if the products and processes are consistent and show the desired quality. The focus of
the control should not only be on the final product but also on the in-process control and on the
intermediate products [53].
Figure 1.2 visualizes how the pharmaceutical unit operations (in black boxes), process parameters,
and quality attributes are connected. Figure 1.2 and the above mentioned procedure are only rec-
ommendations and are not complemented. Depending on the drug product and the manufacturing
process, the QbD can be extended arbitrarily. A critical consideration is helpful for determine the
factors / parameter that should be measured. During the repetition of a process it makes for ex-
ample sense to check the operating parameters. Sometimes (for example during a scale-up process)
it pays out to measure the material attributes of the output instead of observing the operating
parameters. In this case the critical material attributes should be considered as a control strategy
and not the operating parameters due to the fact that they are going to change by using another
machine [54].
A helpful tool during the QbD process is the PAT. Leuenberger for example used PAT years before
the term QbD came into play. That time, Leuenberger developed a device to measure the power
consumption during a wet granulation process. He observed, that the statistical variances between
the batches were reduced with respect to granule size distribution if the power consumption profile
was identical among the batches [25]. PAT requires to collect information during a process. This
information are studied and the gained knowledge should help to control and monitor the process to
ensure desired product quality [54,55]. With this respect, PAT is a tool for a better understanding
of the process.
Yu predicted that the knowledge about mechanical properties of the drug and excipients are going
to become more important in the future [56]. The mechanical properties play an important role
within a solid dosage form. Different methods were presented in the past to gain such knowledge
about mechanical properties [57].
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Figure 1.2: Quality by design. The API and the excipients are characterized by raw material
attributes. During the processing of this powder blend, PAT is a helpful tool for a better under-
standing of the process. The collected information during a process has to be connected to the
resulting quality attributes. The gained knowledge allows to control and monitor the process that
desired product quality can be ensured [54–56].
13
CHAPTER 1. INTRODUCTION
1.4 Special applications
Among pharmaceutical dosage forms, tablets are the most popular dosage form. They are easy
and cost-efficient to produce and they can be easily self-administered by the patient. Furthermore,
tablets are noninvasive in comparison to, for example, parenteralia. The API is protected from
environmental conditions, the release of the API can be controlled and the dosage form is stable
enough to be packed and transported. Under adequate storage conditions, tablets can be stable
over years [58].
A special tablet type is the ODT, which is defined as followes by PhEur [9]:
"Orodispersible tablets are uncoated tablets intended to be placed in the mouth, where
they disperse rapidly before being swallowed."
According to PhEur the ODTs should disintegrate within 3 min when tested with the disintegration
test using water [9]. The FDA Guidance for industry gives even a more precise definition of an
ODT. According to the FDA, an ODT should disintegrate within 30 s and the tablet weight should
be below 500 mg [59].
Conventional tablets can give troubles to certain patient groups, particularly to pediatrics and
geriatrics due to swallowing problems. A study with 6158 tested subjects that were consulting a
general practitioner found, that 26% of total tested patients complained about swallowing problems
[60]. The number of patients with swallowing problems fluctuates quiet heavily between the different
studies. The reasons for the swallowing problems are manifold. Swallowing problems can be caused
by psychological factors (anxiety, discomfort) as well as by physical issues [61, 62]. Physical issues
can for example be a reduced salivary flow (e.g. due to an anticholinergic side effect of a drug),
weak muscles, neurogenic disorders, sensory deficits, and so on [61].
Due to numerous advantages, ODTs are preferred to conventional tablets [63]:
• Easy to use and convenient [64]
• Improved compliance [65,66]
• Suitable for pediatrics [67]
• No need of water (advantageous for patients with nausea, travelers) [64]
• Rapid dissolution and onset of action [68]
• Absorbance from the mouth, pharynx, and esophagus and thus increased bioavailability by
bypassing the first pass metabolism [69]
Despite the numerous advantages, ODTs are limited amongst others by insufficient hardness. To
ensure a rapid disintegration, the tablets are often very porous. A high compaction force would
destroy the porous structure. Furthermore, drugs with an unpleasant taste (taste-masking is very
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important for acceptance of formulation) or a controlled release profile are challenging [70,71].
In the 1990s, mono-functional excipients (e.g. cellulose derivates) were used to produce ODTs.
Later on, sugars and polyols (e.g. mannitol, sucrose, xylitol, and maltodextrin) were included in
the ODT formulations. Mannitol played a key role as an excipient for ODTs due to its sweet
taste and cooling sensation in the mouth. Nevertheless, tablets made with mannitol showed low
mechanical hardness due to bad compactability of the substance. Other researchers made use of
co-processed excipients that combined for example a binder with a disintegrant. By improving the
performance of an ODT, different technologies were patented to receive a product with desired
hardness, disintegration time, and palatability [71].
In general, ODTs can be prepared by lyophilization or by direct compression. A choice of such
technologies is presented in Table 1.1. In general, lyophilization results in a highly porous matrix
that dissolves or disintegrates within seconds after contact with water due to the high surface.
Due to the low mechanical stability and high friability, the lyophilisates can not be packed into
"push-through"-blisters. They are sold in "peel-off"-blisters, from which the lyophilisates have
to be removed carefully. In addition, the blister protects the lyophilisates from humidity. The
prices for lyophilized ODTs are higher compared to direct compressed ODTs due to more complex
production technology and more expensive "peel-off"-blisters. In contrast to lyophilized ODTs,
direct compressed ODTs are produced with conventional tablet presses. The resulting tablets are
mechanically robust and hence can be packed into cheaper "push-through"-blisters [71–73].
Another new appearance are orally dispersible films. To produce such a film, water-soluble polymers
are mixed with the API. The liquid is spread on a plate and dried in an oven. The film is
afterwards cut into individual doses. The high moisture sensitivity and the low doses are limiting
this technology [72]. An example that is on the market in Switzerland, is the Risperidon Sandoz R©
Solufilm.
The fast dispersible dosage forms became even more important after the new regulation of the
European Union with respect to pediatric formulations was enacted. The new regulation asks for
appropriate formulations for different subgroups of children. Especially for younger children the
convential tablets and capsules demonstrate a risk for choking. With fast dispersible dosage forms
this risk can be avoided by offering at the same time a convenient formulation [74].
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Table 1.1: Different technologies for the preparation of ODTs by direct compression and lyophiliza-
tion. The table was adapted from [72,73]
Method Technology Preparation Products
Direct
compres-
sion
Flashtab R© Taste-masked API microparticles are blended
with conventional excipients, super disintegrants
(e.g. crospovidone), and swelling agents (e.g.
MCC).
Prevacid R©
Solutab
(Lansoprazole)
Orasolv R© Taste-masked API microparticles are blended
with effervescent material and other excipients
before everything is compacted at low pressure
to maintain a high degree of porosity. Spe-
cial blisters are required due to weakness of the
tablets (6-25 N).
Remeron R© Soltab
(Mirtazapine)
Durasolv R© Taste-masked API microparticles are blended
with or without effervescent material and other
excipients before everything is compacted. In
contrast to the Orasolv R© technology, the com-
paction force is higher, resulting in more robust
tablets that can be packed into push-through
blisters.
Zomig R© oro
(Zolmitriptan)
Wowtab R© Low moldable sugars (quick dissolution) and
high moldable sugars (high hardness) are granu-
lated together to combine the advantages of the-
ses two sugar types. A special humidity treat-
ment follows after the compaction of the tablets.
Benadryl R©
fastmelt
(Diphenhydramine)
Lyophili-
zation
(freeze-
drying)
Zydis R© A water-soluble matrix is mixed with the
API, preformed in a blister, and afterwards
lyophilized. This technology is extended to pro-
tein and peptide products or oral vaccines.
Zofran R© Zydis R©
lingual
(Ondansetron)
Lyoc R© An emulsion is prepared with the API, a lipid
component, a stabilizer, a filler, and a thickening
agent. The oil-in-water emulsion is freeze-dried.
Loperamide-
Lyoc R©
(Loperamide)
Quicksolv R© An aqueous dispersion is prepared with the
API and matrix components. The dispersion is
lyophilized or submerged in alcohol.
Risperidal R©
Quicklet R©
(Risperidone)
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Chapter 2
Aim
FCC is a mesoporous and particulate material which had been used as a filler in paper industry.
The main aim of this thesis was to investigate if this material can be used as a novel pharmaceutical
excipient and to map its applicability. Three inter-related projects were defined in order to reach
the main aim:
(I) Characterization of the physical properties of FCC powder, such as shape, size, porosity, and
specific surface area. The intention was to compare physical properties of FCC with those of
other excipients, such as ground calcium carbonate and MCC powder, in order to pinpoint possible
differences.
(II) Examination of the mechanical properties of FCC, namely compactability and compressibility,
in comparison to other excipients. The aim was to study the influence of the new excipient’s
physical properties on the behavior under mechanical stress in order to gain scientific knowledge
on the influence of FCC’s microstructure for future tablet developments.
(III) Investigation of the applicability of FCC on the examplary model ODT, including production
optimization, such as granulation, for industrial scale-up. According to the achievable properties
of ODTs made with FCC, the objective was to demonstrate a general proof-of-concept for the use
of FCC in other dosage forms.
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A B S T R A C T
In the present study, we aimed to characterize the compressibility and compactibility of the novel
pharmaceutical excipient, functionalized calcium carbonate (FCC). We studied three FCC modifications
and compared the values for compressibility and compactibility with mannitol, microcrystalline
cellulose (MCC), and ground calcium carbonate (CC 330) as well as mixtures of paracetamol and MCC or
FCC at drug loads of 0%, 25%, 50%, 75%, and 100% (w/w). We used Heckel analysis, modified Heckel
analysis, and Leuenberger analysis to characterize the compaction and compression behavior of the
mixtures. Compaction analysis of FCC showed this material to markedly differ from ground calcium
carbonate, exhibiting properties, i.e. plastic deformability, similar to those of MCC. This effect was
attributed to the highly lamellar structure of FCC particles whose thickness is of the order of a single
crystal unit cell. According to Leuenberger parameters, we concluded that FCC-based tablet formulations
had mechanical properties equal or superior to those formulated with MCC. FCC tablets with high tensile
strength were obtained already at low compressive pressures. Owing to these favorable properties (i.e.
marked tensile strength and porosity), FCC promises to be suitable for the preparation of solid dosage
forms.
ã 2014 Published by Elsevier B.V.
1. Introduction
In response to the introduction of the Process analytical
technology Initiative by the Food and Drug Administration (FDA)
andtheQualitybyDesign(QbD)paradigminpharmaceuticalresearch
and development, there is a need for novel, fully characterized
multifunctional excipients for pharmaceutical products (FDA, 2004).
Compaction behavior, i.e. compressibility, compactibility, and
pressure susceptibility, are critical criteria that need to be met to
avoid issues in scale-up or stability of solid dosage forms.
Performance of materials under pressure has been extensively
studied, and the criteria known to account for compression and
compaction behavior have been defined. These criteria are often
used as composite assessment to determine the suitability of
excipients for target formulations.
Compressibility of a material is the relationship between
compaction pressure and tablet porosity (Leuenberger, 1982;
Leuenberger and Jetzer,1984). Several researchers suggested various
equations to describe compressibility (Heckel,1961a; Heckel,1961b;
Cooper and Eaton,1962; Nelson et al.,1955). One of the approaches to
analyze compaction behavior was proposed by Heckel. Inthe present
work, data were analyzed according to the Heckel equation. It is a
popular equation that allows to compare volume reductions among
different materials under constant experimental conditions (York,
1979; Duberg and Nyström,1986).The majoradvantageof theHeckel
equation is the availability of a large reference dataset. This makes
the Heckel equation a convenient tool for analysis and comparison of
different materials. Heckel analysis assumes that the volume
reduction (reduction of compact porosity) under pressure follows
first-order kinetics (Heckel, 1961a; Heckel, 1961b). The reciprocal of
the Heckel slope is defined as the yield pressure of the material and
represents the resistance of a material to deformation (Hersey and
Rees,1971). Susceptibility of a material to pressure can be taken into
account by the modified Heckel equation, which is particularly
suitable for low pressure ranges (Kuentz and Leuenberger, 1999).
Powder compactibility is often assessed by plotting the crushing
strength as a function of compressive pressure (Leuenberger, 1982;
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Leuenberger and Jetzer, 1984). Nowadays, crushing strength is
mostly replaced by tensile strength because tensile strength takes
differences in tablet size into account (Fell and Newton,1968). Jetzer
et al. published an equation to calculate the compactibility and
compression susceptibility. These two parameters provide informa-
tion about the deformation of the material under stress and the
bonding properties of the material (Jetzer et al., 1983).
Therollercompactionprocessleadstothe formationofsecondary
micro-hardened regions in the roller-compacted ribbons of materi-
als, such as magnesium carbonate (Freitag et al., 2004). We assumed
a similar behavior for highly lamellar materials, due to the formation
of local hardening in zones consisting of interpenetrating or
interlocking lamellae. According to this hypothesis, we assumed
the contact surfaces to be a governing factor to achieve compacts of
higher tensile strength even at lower pressures.
Functionalized calcium carbonate (FCC) is a particulate (5–15 mm
in size) material with highly developed surface and internal
structures. It is produced by re-precipitation of inorganic mixed
salts (calcium phosphate in this case) incorporating the starting
material (calcium carbonate) under controlled conditions to form
microporous particles with a specific lamellar surface area of
40–80 m2/g and a porosity of approximately 70%. In a previous study,
we successfully used this substance to produce mechanically robust,
orally dispersible tablets by direct compression (Stirnimann et al.,
2013). In the present study, we characterized compressibility and
compactibility of the novel pharmaceutical excipient FCC.
2. Materials and methods
2.1. Materials
Three different modifications of FCC (VP-OM2501 S01, VP-
OM2501 S02, and VP-OM2501 S03, Omya International AG,
Oftringen,Switzerland) were compared to microcrystalline cellulose
(MCC SANAQ1 102, Pharmatrans Sanaq AG, Allschwil, Switzerland),
calcium carbonate (PharMagnesia CC Type Natura 330, Lehmann &
Voss & Co., Hamburg, Germany), and mannitol (Mannitolum Ph Eur,
Hänseler AG, Herisau, Switzerland). As an active pharmaceutical
ingredient, we chose paracetamol (Acetaminophen USP/Paraceta-
mol Ph Eur Powder, Mallinckrodt, Saint Louis, MO, USA).
Hydroxypropyl methyl cellulose (HPMC) E5PLV (Colorcon
Limited, Dartford Kent, UK) was used as a binder for wet
granulation. Magnesium stearate (Novartis, Basel, Switzerland)
was used as a lubricant for tableting. For particle-size distribution
measurements, we used isopropyl myristate (Hänseler) as a
dispersant. Mercury (Sigma-Aldrich, Munich, Germany) was used
as a non-wetting liquid for porosimetry measurements.
2.2. Methods
2.2.1. Characterization of raw materials
Scanning electron microscopy (SEM) images were obtained
using an FEI/Philips XL30 FEG instrument (Philips, Eindhoven,
Netherlands). The samples were sputtered with a 40 nm gold layer
by a sputter coating device (MED 020, BalTec, Balzers, Liechten-
stein) before microscope imaging.
Apparent true densities of the substances were determined by
helium pycnometry (Micromeritics AccuPyc 1330, Norcross, GA,
USA). Before the measurement, substances were dried overnight
(12–15 h) under nitrogen flow in a vacuum drying cabinet type
KVTS 11 (Salvis, Oftringen, Switzerland).
Particle-size distribution was determined with the Mastersizer
X long bed laser diffractometer (Malvern Instruments, Malvern,
Worcestershire, UK). FCC, MCC, CC 330, and paracetamol were
dispersed in isopropyl myristate and analyzed by using the small
volume sample presentation unit (Malvern Instruments). For
mannitol, we used a dry powder feeder (Malvern Instruments).
Measurements were performed in triplicate.
A Nova 2000e (Quantachrome Instruments, Boynton Beach, FL,
USA) was used to quantify the specific surface area of FCC with the
five-point BET (Brunauer–Emmett–Teller) method. After degassing
the samples for 12–15 h at room temperature, they were measured
in duplicates with nitrogen at constant temperature (77.4 K).
Mannitol, MCC, CC 330, and paracetamol were not assessed due to
the limit of resolution of the instrument (<0.01 m2/g).
Pore-size distribution of the substances was determined with an
Auto Pore IV 9500 mercury porosimeter (Micromeritics Instrument,
Norcross, GA, USA). Low-pressure mercury intrusion ranged from
3.59 kPa to 206.64 kPa. During high-pressure mercury intrusion, the
pressure ranged from 206.64 kPa to 206.78 MPa. For both high- and
low-pressure intrusion, equilibration time was set to 10 s.
2.2.2. Granulation of FCC
Granulation of FCC was achieved by roller compaction (Chilso-
nator IR220 roller compactor, Fitzpatrick, Elmhurst, IL, USA). The roll
pressure was set to 20 bars at a roll gap of 1 mm and a roll speed of
4 rpm. The speed of the horizontal feed screw was set to 25 rpm, and
the vertical feed screw moved with a speed of 120 rpm. To ensure
constant powder flow to the horizontal feeding screw within the
powder chute, we used a stirring device of type RE162 (IKA
Labortechnik, Janke & Kunkel GmbH & Co. KG, Staufen, Germany) at
35 rpm. High-shear mixer granulation of FCC was carried out with an
Oystar Micromix high-shear mixer (Hüttlin GmbH, Schopfheim,
Germany). The binder (HPMC E5PLV) was dissolved in distilled water
using a magnetic stirrer IKAMAG1 RCT (IKA Labortechnik, Janke &
Kunkel Gmbh & Co. KG) to obtain a 4% (w/w) solution. The binder
solutionwas foamed with pressurized air (approximately 8 bars) in a
Tornador1 Z-011 foam gun (Bendel Werkzeuge, Bad Bevensen,
Germany). FCC S02 was granulated with 5% (w/w) HPMC E5PLV. The
foamed binder was added to the powder at a speed of 5.3 g/min with
a peristaltic pump (Vario-Pumpsystem-Antrieb, Ismatec SA, Glatt-
brugg, Switzerland). The impeller speed was approximately 150 rpm
andthechopperspeedwasapproximately1500 rpm.Afterwards, the
granules were dried at 60 C in a Heraeus UT 6200 drying oven
(Sorvall Heraeus Instruments, Hanau, Germany) until loss on drying
(LOD) was approximately 2%. LOD was determined gravimetrically
with a Mettler LP 16 infrared lamp and a Mettler PE 360 balance
(Mettler Instruments, Greifensee, Switzerland).
After roller compaction and high-shear granulation, ribbons
and granules were milled with a Fitz1Mill comminutor L1A
(Fitzpatrick) at a speed of approximately 500 rpm. Granules were
sieved for 10 min at an amplitude setting of 46 to obtain particles
sized between 180 mm and 500 mm (Retsch Vibro, Schieritz &
Hauenstein AG, Arlesheim, Switzerland).
2.2.3. Tablet preparation
Prior to compaction, each powder was sieved through a
1000 mm sieve to eliminate agglomerates. Powders and granules
were dried overnight (12–15 h) under nitrogen flow in a vacuum
drying cabinet of type KVTS 11 (Salvis).
Mixtureswere prepared by blendingexcipientswithparacetamol
to obtain paracetamol contents of 25% (w/w), 50% (w/w), 75% (w/w),
and 100% (w/w). Furthermore, a reference formulation without
paracetamol was prepared. Powders were mixed for 10 min in a
tumbling mixer (Turbula T2C, Basel, Switzerland) at 32 rpm.
All powders and granules were compressed using a Styl’One
105 mL tablet press (Medel’Pharm, Beynost, France) with 10 mm
round flat tooling. Analis software version 2.01 (Medel’Pharm) was
used to operate the instrument and monitor the process. Due to the
highly variable porosities of the raw materials, tablets with varying
porosities were obtained at defined pressure. Therefore, we decided
to hold the tablet volume constant at the lowest compressive
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pressure. With an electronic balance type AX204 DeltaRange
(Mettler Toledo), we manually (except for the granules) weighed
the necessary amount of substance to obtain a tablet with a height of
6 mm at a compressive pressure of 6.37 MPa (0.5 kN). We used this
sample mass for all tablets and all formulations over the whole
compressive pressure range. FCC S02 granules were compacted
using a feed shoe. Table 1 shows the tablet weight for each
formulation (mean  SD of n = 3 measurements).
The formulations with and without paracetamol were com-
pacted in triplicate at 10 and 16 different compressive pressures
ranging from 6 MPa to 500 MPa. Compressive pressure step-up was
stopped if lamination occurred below 500 MPa. Punches were
manually lubricated with magnesium stearate. For the automated
process, magnesium stearate (0.5%, w/w) was mixed into the
granules using a tumbling mixer (Turbula T2C) for 3 min at 32 rpm.
To compress the tablets, we used the minimum possible dwell time
achievable on our tablet press; rise and fall of the lower punch was
set to 750 ms keeping the “maintain” phase set to “0” to simulate
the shortest possible dwell time.
During tablet preparation and characterization, the tempera-
ture was kept between 24 C and 34 C and relative humidity
between 31% and 57%.
2.2.4. Tablet weight, diameter, height, and crushing force
Immediately after tablet compression, we determined the weight,
diameter,andheightof thetablets.Thetablets(n = 3) wereweighedon
an electronic balance type AX204 DeltaRange (Mettler Toledo).
Diameter and height of the tablets were determined with a
micrometer screw (Mitutoyo Model CD-15CPX, Kawasaki, Japan).
Before measuring the crushing force, the tablets were allowed to
expand for at least 1 h. If the crushing force of the tablets was lower
than 400 N, we used a tablet hardness tester (8M, Dr. Schleuniger
Pharmatron, Solothurn,Switzerland)with a speed of impact 1 mm/s
(default value). In case of harder tablets, the tablet crushing force
was analyzed on the Styl’One 105 mL tablet press (Medel’Pharm). To
this end, the height was set to 13.5 mm, and the thickness of the
tablet was set to 9 mm. When the punch had reached the lowest
position, we placed the tablet vertically in the die, i.e. on a cylindrical
edge, and proceeded with the compression sequence. The speed of
impact was 0.3 mm/s in average for all measurements performed
with Styl’Onetablet press. The maximumforceappliedwastheforce
needed to break the tablet. Both methods yielded the same crushing
force for identical tablets despite the differences in impact speed.
2.2.5. Heckel, modified Heckel, and Leuenberger analyses
Using the software package OriginPro version 8.5 (OriginLab
Corporation, Northampton, MA, USA), the Heckel equation (Heckel,
1961a,b) was fitted according to equation (1):
ln
1
1  p
 
¼ k  s þ A (1)
where r is the density of the tablet (g/cm3), k is the Heckel
parameter (MPa1), s is the compressive pressure (MPa), and A is a
constant. We considered all data points for compressive pressures
between 50 MPa and 200 MPa.
Density (r) of the tablet was calculated with equation (2):
r ¼ m=pr
2h
 
rtrue
(2)
where m is the tablet mass (g), r is the tablet radius (cm), h is the
tablet height (cm), and rtrue is the true density of the substance
forming the skeletal structure of the porous tablet (g/cm3).
Mean yield pressure (sy, MPa) was calculated according to
equation (3):
sy ¼ 1k (3)
where k is the Heckel parameter (MPa1).
With the modified Heckel equation (Kuentz and Leuenberger,
1999), the relative critical density (rrc) and constant (C, MPa1)
were calculated according to equation (4):
s ¼ 1
C
rrc  r  ð1  rrcÞln
1  r
1  rrc
  
(4)
where s is the compressive pressure (MPa) and r is the relative
density of the tablet. Relative critical density is a parameter that
defines a rigidity threshold and indicates the pressure susceptibil-
ity, i.e. the lower the value of rrc, the earlier the onset of probability
to form a stable pharmaceutical compact. The data between 6 MPa
and 200 MPa were considered for the modified Heckel analysis.
By means of the Leuenberger equation (Jetzer et al., 1983),
compactibility (stmax) and compression susceptibility (g) were
calculated using equation (5):
st ¼ st max  ð1  eðgsrÞÞ (5)
where st is the radial tensile strength (MPa), stmax is the tensile
strength (MPa) when s (compressive pressure) ! 1 and r
(relative density) ! 1, g is the compression susceptibility (MPa
1), r is the relative density of the tablet, and s is the applied
compressive pressure (MPa). Data points over the entire compres-
sion range used were included in the calculation.
2.2.6. Tensile strength and porosity
Tensile strength was calculated according to equation (6):
st ¼ 2  Fp  d  h (6)
where st is the radial tensile strength (MPa), F is the crushing force
(N), d is the tablet diameter (mm), and h is the thickness of the
tablet (mm).
With the aid of Analis software 2.01 (Medel’Pharm), we
calculated the porosity of the tablets in accordance with
equation (7):
e ¼ 1  m=pr
2  h 
rtrue
  !
 100 (7)
where e is the porosity (%), m is the tablet weight (g), r is the radius
of the tablet (cm), h is the height of the tablet (cm), and rtrue is the
true density of the substance (g/cm3).
Table 1
Weight of tablets.
Formulation Weight (mg)  SD
Mannitol 480.94  0.62
MCC 325.09  0.52
CC 330 730.09  0.76
FCC S01 317.07  1.78
FCC S02 295.94  1.79
FCC S03 314.24  4.26
FCC S02 granules RC 377.03  0.94
FCC S02 granules HSM 409.67  1.58
100% Paracetamol 448.36  1.21
75% Paracetamol + 25% MCC 389.63  1.29
50% Paracetamol + 50% MCC 360.90  0.92
25% Paracetamol + 75% MCC 326.01  0.59
75% Paracetamol + 25% FCC S02 399.38  1.81
50% Paracetamol + 50% FCC S02 360.43  0.91
25% Paracetamol + 75% FCC S02 329.72  0.91
CC: calcium carbonate; FCC: functionalized calcium carbonate; HSM: high-shear
mixer; MCC: microcrystalline cellulose; RC: roller compaction.
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2.2.7. Pore-size distribution in tablets
To determine the distribution of pore sizes, the excipients (FCC
S01, FCC S02, FCC S03, CC 330, MCC, and mannitol) were compacted
without magnesium stearate at 12.73 MPa, 63.66 MPa, and
127.32 MPa using a Styl’One tablet press (Medel’Pharm). The
tableting procedure is detailed in Section 2.2.3.
Pore-size distribution of the tablets was determined by
mercury porosimetry as described in Section 2.2.1.
Pore size distribution of FCC powders are mostly bimodal
(Ridgway et al., 2006), characterizing intra- and interparticle voids.
To distinguish between intraparticle and interparticle pores, the
data curve of the mercury porosimetry plot (pore diameter versus
pore volume) was fitted with OriginPro version 8.5 (OriginLab).
Fig. 1 shows the bimodal pore size distribution of FCC and the user-
defined bimodal curve fit of equation (8). Equation (8) is
constructed as a sum of two log normal distributions.
y ¼ y0 þ
1
2
Ae1=2 lnðx=xcÞ
2ð Þ=w2ð Þ ffiffiffi2pffiffiffiffi
p
p
wx
þ A1e
1=2 ln x=xc1ð Þ2ð Þ=w12ð Þ ffiffiffi2pffiffiffiffi
p
p
w1x
" #
(8)
where x is the pore size (mm), y is dV/dlog D pore volume (mL/g), xc
and xc1 are fitting parameters indicating the maximum of
distribution, and other constants are for fitting purposes only
(without physical meaning).
To find the intersection point (xi) of this bimodal curve, we
solved equation (8). After fitting equation (8) to experimental data,
the parameters for two distributions were determined. The
intersection point (xi) of two curves is a solution of equation (9):
1
2
Aeð1=2Þððlnðx=xCÞ
2Þ=w2Þ ffiffiffi2pffiffiffiffi
p
p
wx
¼ 1
2
A1eð1=2Þððlnðx=xC1Þ
2Þ=w12Þ
ffiffiffi
2
p
ffiffiffiffi
p
p
w1x
(9)
Equation (9) has two solutions (x1 and x2) as shown in equation
(10).
x1 ¼ e
ðlnðxc1=xc Þw1þ
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
2lnððAw1Þ=ðA1wÞÞw2w122w4lnððAw1 Þ=ðA1wÞÞþw2lnðxc1=xc Þ2
p
Þw1
w2
1
w2
x2 ¼ e
ðlnðxc1=xc Þw2þ
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
2lnððAW1 Þ=ðA1WÞÞW2W122W4lnððAW1Þ=ðA1WÞÞþW2lnðxc1=xc Þ2
p
ÞW1
W2
1
W2
(10)
Xi is the solution (either x1 or x2), which is located between xc and
xc1 (Figure 1).
The area under the curve (AUC) was calculated using Excel 2010
(Microsoft Corporation, Redmond, WA, USA) using the linear
trapezoidal rule and the data points from the mercury porosimetry
plot. All data points between zero and the intersection point (xi)
were included to calculate intraparticle AUC (0 < x < xi). The values
exceeding the intersection point (xi) were used to calculate
interparticle AUC (xi< x < mean median particle size). The ratio
between inter- and intraparticle AUC indicated the pore distribu-
tion.
3. Results
3.1. Characterization of raw materials
Fig. 2 shows SEM pictures of the three different types of FCC
particles. Typically, the FCC particles consisted of thin lamellae,
forming a porous meshwork. FCC S01 and FCC S02 were similar, but
FCC S03 had a more compact structure of lamellae and solid
inclusions.
Table 2 summarizes the apparent true densities, mean median
particle sizes, specific surface areas, core voids, and stratum/
interparticle voids of the substances used.
Fig. 3 presents the porosimetry plots of the raw materials in
powder form. The plots of MCC, mannitol, and CC 330 showed only
one peak (pore diameter above 500 nm). In contrast, the plots of FCC
showed two peaks; one below a pore diameter of 500 nm and one
above 500 nm. Furthermore, the porosimetryplots indicated thatthe
three different batches of FCC exhibited a different pore size
distribution below a pore diameter of 500 nm. In the range of 10 nm
to 200 nm, FCC S01 showed a higher volume of larger pores (e.g.
100 nm) than of very small pores (e.g. 10 nm), whereas FCC S03 was
the opposite, with a higher pore volume of very small pores
apparently. Under pressure, these effects were amplified. In powder
form or at very low compressive pressure (12.7 MPa), FCC S02
showed a higher volume of larger pores than of small pores. At higher
compressive pressure (127.3 MPa), we observed a higher volume of
very small pores than of larger pores (data not shown).
3.2. Tablet properties
3.2.1. Comparison of FCC modifications
Table 3 summarizes the values for tensile strength and porosity
for the different FCC/paracetamol mixtures at two compressive
pressure settings. Porosities of tablets were very similar for all FCC/
paracetamol mixtures at either pressure. We observed a trend
towards higher tensile strength for FCC S02, especially in the lower
pressure range. Under these conditions, reliable data were
obtained only with this material. Therefore, we used FCC S02 for
a mechanistic follow-up study.
3.2.2. Heckel, modified Heckel, and Leuenberger analyses
Table 4 shows the Heckel, modified Heckel, and Leuenberger
parameters of the tablets. Our data exhibited a high value for the
goodness of fit (R2). The Heckel values (k) for formulations without
paracetamol were highest when using MCC, followed by mannitol.
The carbonates (FCC and CC) showed lower Heckel values than
MCC and mannitol, but FCC reached higher values than CC 330. The
mean yield pressure was approximately 180 MPa for MCC and
mannitol. For the carbonates, mean yield pressure ranged from
294 MPa to 513 MPa (CC 330). Fig. 4 shows a comparison of the
initial non-linear part of the Heckel-plot for the different types of
FCC. The curves of FCC S01 and FCC S02 were comparable whereas
FCC S03 shows less non-linearity. Modified Heckel analysis showed
that the values for C were smaller than those for k, but the order
was the same (except within FCC). FCC exhibited the lowest critical
relative density (0.125–0.154), followed by MCC (0.253), CC 330Fig. 1. Schematic representation of the bimodal curve fit.
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(0.525), and mannitol (0.594). Pure paracetamol tablets could not
be compacted over the whole compression range due to
lamination. Paracetamol/MCC tablets showed higher values for k
and C (and therefore lower values for the mean yield pressure) than
paracetamol/FCC S02 tablets. In each case, the values for C were
significantly lower than the values for k. Furthermore, we observed
a trend towards higher k and C values with decreasing amounts of
paracetamol.
Critical relative densities of paracetamol tables formulated with
either MCC or FCC S02 at identical mixing ratios were similar. The
higher the amount of paracetamol in a formulation, the higher was
the relative critical density of the resulting tablets.
In general, the quality of fit was better for the modified Heckel
equation than for the Heckel equation.
In the Leuenberger analysis (Table 4), compactibility (stmax)
values for the formulations without paracetamol exceeded 10 for CC
330 (3.27103MPa), FCC S03 (13.92 MPa), MCC (12.40 MPa), and
FCC S01 (11.88 MPa). FCC S02 achieved a compactibility value of
8.55 MPa, and mannitol showed by far the lowest value (2.77 MPa).
For compression susceptibility (g), FCC S02 showed a significantly
higher value (13.38103MPa1) than the other materials, with
MCC achieving a value of 7.56103MPa1, followed by FCC S01
(6.19103MPa1), FCC S03 (5.45103MPa1), mannitol (4.2310
3MPa1), and CC 330 (0.001103MPa1).
By adding and increasing the amount of paracetamol in a
formulation, compactibility (stmax) values decreased. For the same
mixing proportions, compactibility values were not significantly
different for paracetamol formulations based on either MCC or FCC
S02. Compression susceptibility (g) was significantly higher for
FCC S02 formulations than for MCC formulations. The smaller the
amount of paracetamol in a formulation, the higher was the value
for compression susceptibility.
Fig. 2. (a–c) SEM pictures of (a) FCC S01, (b) FCC S02, and (c) FCC S03 (magnification: 6702).
Table 2
Apparent true density (skeletal density), mean median particle size, specific surface area, core voids, and stratum/interparticle voids of the substances.
Substance Apparent true density
(g/cm3)
Mean median particle size (mm)  SD Specific surface area
(m2/g)  SD
Core voids
(%, v/v)
Stratum and interparticle voids
(%, v/v)
Mannitol 1.4849 121.31  0.24 <LOD 0 100
MCC 1.5476 102.91  1.22 <LOD 0 100
CC 330 2.7144 10.15  0.24 <LOD 0 100
FCC S01 2.6893 14.15  0.01 37.89  0.04 9 91
FCC S02 2.7259 6.80  0.03 56.22  0.10 11 89
FCC S03 2.5054 9.19  0.04 59.16  0.19 9 91
Paracetamol 1.292 106.99  0.32 <LOD 0 100
CC: calcium carbonate; FCC: functionalized calcium carbonate; LOD: limit of detection; MCC: microcrystalline cellulose.
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3.2.3. Porosities and tensile strength of tablets
Fig. 5(a) shows the summative percentages of intra- and
interparticle porosities as a function of compressive pressure for
the formulations without paracetamol. Porosities of mannitol
tablets (and in part also of MCC tablets) were much lower than the
porosities of the calcium carbonate tablets. At low pressures
(<10 MPa), FCC tablets had a porosity of more than 70% (v/v). At a
compressive pressure of 400 MPa, porosities of CC 330 and FCC
tablets were comparable (approximately 25% v/v). At the low range
of compressive pressure, we observed a marked decrease of
porosity for MCC tablets, and the change of porosity in response to
altered compressive pressure was less marked for the other
substances.
Fig. 5(b) is the correlation plot between compressive pressure
and tablet porosity for the formulations with paracetamol.
Depending on mixing ratios, MCC tablets showed a porosity of
40% (v/v) to 57% (v/v) at low compressive pressures. At the same
pressure range, FCC S02 tablets reached porosities between 43% (v/
v) and 77% (v/v). At around 240 MPa, porosity of all MCC
formulations was approximately 10% (v/v). Tablets prepared with
FCC S02 showed significantly higher porosities at the same
pressure. At a compressive pressure of 240 MPa, tablets containing
75% paracetamol and 25% FCC S02 showed a porosity of 16.8% (v/v),
tablets containing 50% paracetamol and 50% FCC S02 had a porosity
of 22% (v/v), and tablets containing 25% paracetamol and 75% FCC
S02 reached a porosity as high as 28% (v/v). Pure FCC S02 showed a
porosity 3.5 times higher than that determined for the formula-
tions with pure MCC at the same compressive pressure.
Fig. 5(c) shows the tensile strength as a function of compressive
pressure for formulations without paracetamol. Mannitol and CC
330 exhibited very low tensile strength, even at high compressive
pressures. Compared to CC 330, FCC reached high values for tensile
strength that were similar to those of MCC. At low compressive
pressures (below 100 MPa), the tensile strengths of FCC S02 and
MCC were in the same range. FCC S03 was comparable to MCC at
higher compressive pressures (above 200 MPa). Compressive
pressure and tensile strength correlated in a linear fashion. For
all FCC-based formulations, and especially for pure FCC powders,
an atypical crack propagation of the tablets occurred during the
crushing force measurement, i.e. the breaking pattern was more
typical of a highly homogeneous, brittle material similar to
porcelain. We assumed this effect to be responsible for the more
variable crushing force measurements for tables formulated with
FCC.
Fig. 5(d) is the correlation plot between compressive pressure
and tensile strength for the mixtures with paracetamol. Below a
pressure of 50 MPa, the tensile strengths of pure MCC and pure FCC
S02 were comparable. Above 50 MPa, MCC tablets reached a higher
tensile strength. However, below a compressive pressure of
180 MPa, all paracetamol tablets formulated with FCC S02
(independent of the mixing ratio) exhibited a tensile strength
superior to that measured for MCC/paracetamol formulations.
Above a compressive pressure of 180 MPa, MCC/paracetamol
tablets showed a higher tensile strength than FCC S02/paracetamol
tablets. In general, tensile strength increased with increasing
proportions of FCC S02 or MCC.
3.2.4. Porosity and tensile strength of tablets prepared from granules
Porosity of tablets prepared from granulated material was
generally lower than that of tablets formulated with FCC powder
(Fig. 5a). If granules produced by roller compaction were used,
porosity of the tablets was less markedly reduced than if granules
produced by high-shear granulation were used, but in either case,
the loss of porosity was below 10%.
In all cases, tensile strength of tablets made of roller-compacted
granulates was similar to the tensile strength of tablets formulated
Fig. 3. Porosimetry plot of raw materials in powder form (for FCC modifications, the
data points above 10 mm are not shown).
Table 3
Tensile strength and porosity of paracetamol mixtures with FCC S01, FCC S02, and FCC S03.
Mixtures Mean compressive pressure (MPa) Tensile strength (MPa) Porosity (%)
25% P + 75% FCC S01 7.25  0.07 0.109  0.005 66.12  0.08
94.33  0.55 1.958  0.015 40.23  0.21
50% P + 50% FCC S01 7.15  0.09 <LOD 55.61  0.04
93.32  0.27 0.910  0.012 31.97  0.03
75% P + 25% FCC S01 6.99  0.15 <LOD 43.91  0.21
91.98  0.55 0.474  0.043 24.36  0.12
25% P + 75% FCC S02 7.06  0.05 0.199  0.010 67.52  0.06
93.24  0.12 2.187  0.079 40.01  0.27
50% P + 50% FCC S02 6.90  0.13 0.113  0.006 56.54  0.46
92.08  0.13 1.017  0.022 31.79  0.19
75% P + 25% FCC S02 7.05  0.10 <LOD 43.64  0.39
92.34  0.41 0.423  0.007 23.46  0.02
25% P + 75% FCC S03 7.19  0.11 0.147  0.000 64.82  0.17
93.90  0.11 2.068  0.079 40.54  0.19
50% P + 50% FCC S03 7.18  0.29 0.085  0.000 53.80  0.06
92.93  0.23 0.976  0.036 31.80  0.35
75% P + 25% FCC S03 7.16  0.26 <LOD 41.68  0.41
92.38  0.42 0.351  0.011 23.57  0.26
FCC: functionalized calcium carbonate; LOD: limit of detection; P: paracetamol.
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with pure FCC S02 powder. However, granulation by the high-shear
mixer noticeably lowered tensile strength of the tablets (Fig. 5c).
4. Discussion
4.1. Pore volume distribution and morphology of raw materials
The bimodal distribution of pore sizes within FCC particles (see
Figs. 1 and 3) for all types of FCC indicates that individual particles
consist of denser cores, i.e. voids <500 nm (core voids) surrounded
by a porous layer with larger pores and channels, i.e. voids >500 nm
(stratum voids). The interparticle voids are also classified to be
>500 nm. Clear distinction between stratum and interparticle
voids is difficult. In previous investigations by Ridgway et al., these
distribution patterns were classified as inter- and intraparticle
voids (Ridgway et al., 2004).
Pore volume distribution and morphology of stratum voids are
specific to each FCC type, resulting from specific changes in
production parameters. For all other substances studied, we only
detected interparticle voids, i.e. the voids between individual
particles.
4.2. Tablet properties
4.2.1. Tablets without paracetamol
Heckel and modified Heckel analyses of the tablets without
paracetamol showed MCC (sy = 175 MPa) and mannitol (sy = 181
MPa) to have elastic/plastic deformation behavior under pressure,
whereas all carbonates were brittle. The sy values were
significantly smaller for FCC (sy350 MPa) than for CC 330
(sy500 MPa), indicating the plastic behavior of FCC particles.
Nevertheless, our values for mean yield pressure were rather high
compared to other reports (Ilkka and Paronen, 1993; Paronen
Heckel, 1986; Sonnergaard, 1999). These higher values resulted
from the wider range of compressive pressure used in our study.
The pressure range for plastically deforming materials was
reported to be 40–135 MPa, and fragmentation occurs at a yield
pressure range between 340 MPa and 430 MPa (Jain, 1999). Values
determined for the relative critical density showed that FCC can be
compacted into a stable tablet at a lower pressure than MCC, which
is a sign of plastic deformation behavior. For mannitol and CC 330,
higher pressure was needed to form robust compacts.
Using Leuenberger analysis, we showed that the compacts based
on FCC S03 had the highest mechanical resistance (stmax), followedTa
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Fig. 4. Comparison of Heckel plots for FCC types in the lower pressure range (values
are means  SD; n = 3).
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by MCC, FCC S01, and FCC S02. These results were confirmed by the
tensile strength plot (Fig. 5c). Tensile strength was comparable for
MCC and FCC S03, especially above a compressive pressure of
200 MPa. Fig. 6 shows a schematic representation of FCC particles
and two types of possible contact surfaces. We assumed that the
particles moved closer to each other under low compressive
pressure, and interlocking structures were formed between the
lamellae (type I). The reasons for the differences in the non-linear
part of the Heckel-plot (Fig. 4) could be due to densification by
fracture of brittle lamellae followed byplastic deformation at higher
compressive pressures. The initial differences of the density at
7.5 MPa for FCC S03 was attributed to less lamellae on the surface of
FCC S03 particles (see Fig. 2). More spherical FCC S03 is better
packed under low pressure (<20 MPa) as compared to FCC S01 or
FCC S02. Under higher compressive pressure, the compact densities
were similar. This indicates brittle deformation of lamellae under
pressure. According to Heckel analysis (linear part), particles
deform by fragmentation under higher compressive pressure,
and the disruption of the particle provides a new contact surface for
potential bonds (type II, Fig. 6). With FCC, we observed a stepwise
increase of the tensile strength. For example, FCC S03 showed such a
step at a compressive pressure between 150 MPa and 200 MPa. We
assumed that the FCC S03 particles broke/collapsed more frequent-
ly than FCC S01 or FCC S02 particles at this compressive pressure.
Due to the large volume of very small intraparticular pores in FCC
S03 (Fig. 3), a large surface area for type II bonds would be available
after particle disruption, resulting in a strong grip between the
particles (Fig. 6, type II). As a consequence, tensile strength
increased at higher compressive pressure. In contrast, FCC S01
and S02 showed a more extensive volume of larger pores than very
small pores at low compressive pressures (Fig. 3). We speculated
that under low compressive pressure, these larger pores of FCC S01
and S02 provided a markedly larger contact surface for possible
bonds (type I) than did FCC S03 particles. FCC S03 exhibited a much
smaller volume of largepores;hence the contact surface for possible
bonds was limited under low compressive pressures.
Possible reasons for the marked tensile strength achieved with
FCC could be (1) the surface texture in the stratum of FCC (rough,
lamellae) and (2) the smaller size of the FCC particles. FCC particles
were around 10 times smaller than MCC particles and therefore
possessed a larger surface area in relation to the same volume.
Fig. 5. Summative percentage of inter- and intraparticle porosity (v/v) (a, b) and tensile strength (c, d) of tablets compressed at different pressures.
Fig. 6. Schematic representation of FCC particles and the 2 types of contact surfaces
(gray). (For interpretation of the references to color in this figure legend, the reader
is referred to the web version of the article.)
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Thus, the potential contact surface area of FCC is considerably
larger than that associated with MCC, CC 330, or mannitol.
Leuenberger analysis revealed that compression susceptibilities
(g) varied significantly among the different substances. FCC S02
showed marked compression susceptibility with a value almost
double the value for MCC, indicating that the plateau of tensile
strength was reached faster than with the other substances. This
finding was confirmed by the fact that FCC S02 showed capping
above 250 MPa as the pressure increased. Below 50 MPa, FCC S02
yielded tablets with a high tensile strength, comparable or even
superior to the tensile strength of MCC tablets (Fig. 5c).
Figs. 5a and 5c show certain limitations for MCC and mannitol
at higher compressive pressures. Above 250 MPa, the tensile
strength and porosity curves for MCC and mannitol started to level
off and reached a plateau. FCC and CC 330 did not show such
behavior at higher pressures. At 400 MPa, MCC had a porosity of
only approximately 10%, in contrast to FCC and CC 330 whose
porosities still exceeded 20%. This resulted in a higher volume
(available for drug loading, for example), whilst maintaining high
compact tensile strength. Above 400 MPa, porosities of FCC and CC
330 were comparable because the core and stratum voids of FCC
broke down at these pressures.
4.2.2. Paracetamol tablets
Because paracetamol crystals are brittle (Duberg and Nyström,
1986; Prasad et al., 2001), the tablets increasingly deformed by
fragmentation as paracetamol amounts were increased. The higher
the proportion of paracetamol in the tablets, the higher was the
critical relative density. This indicated that the compressive
pressure had to be increased to obtain a robust compact.
By increasing the proportion of paracetamol in the formula-
tions, mechanical resistance (stmax) of the tablets decreased.
Paracetamol is known to compensate mechanical stress by elastic
recovery rather than by fracture or particle rearrangement (Leigh
et al., 1967; Malamataris et al., 1984; Bangudu and Pilpel, 1985;
Malamataris et al., 1996; Carless and Leigh, 1974). Compression
susceptibility (g) was higher for the paracetamol formulations
with FCC S02 than for those with MCC. Therefore, FCC S02
produced stronger compacts even at low pressures. With lower
amounts of FCC S02 in the formulation, the contact surface area to
form new bonds is also decreased. Thus, to produce harder tablets,
higher compaction pressure is necessary to force the FCC lamellae
from the stratum into contact with other FCC particles. Compres-
sion susceptibilities of paracetamol formulations based on MCC
were much more strongly influenced by increasing the paraceta-
mol ratio than were paracetamol/FCC S02 formulations.
With respect to porosity changes upon compaction, FCC S02
was less pressure-sensitive than MCC. We assumed that the
lamellar surface of FCC S02 acted as an energy dissipator to
compensate the stress on pressure increase. Therefore, porosity
decreased slowly by increasing the pressure.
Fig. 5(d) shows that pure MCC reached higher tensile strengths
than pure FCC S02. In combination with paracetamol, FCC S02
reached a higher tensile strength in the low compressive pressure
range compared to MCC. This effect supports the hypothesis that
the contact surface area is a governing factor for a compact’s
mechanical stability. Moreover, the higher the proportion of
paracetamol in a formulation, the earlier (at lower pressures) was
the loss of mechanical stability, i.e. because of lamination, capping,
etc.
4.2.3. Porosity and tensile strength of tablets prepared from granules
Over the entire range of compressive pressure, the tablets made
from the roller-compacted FCC S02 granules showed higher
porosities and higher tensile strengths than the tablets formulated
with FCC S02 granules produced by the high-shear process. The
reason for this was that roller-compacted FCC S02 granules
possessed a large surface area allowing a strong grip between
particles and the formation of stronger tablets already at lower
pressures. Furthermore, the high shear forces in the mixer partially
destroyed the stratum lamellae of FCC S02 and thus reduced the
contact area. Granulation by roller compaction of FCC particles
improved the flowability (data not shown) and retained the
marked mechanical strength of the resulting FCC tablets. This
property is unique to FCC, as a loss of tablet strength with other
materials after roller-compaction granulation has been reported
for all available excipients, including MCC.
5. Conclusion
The term FCC encompasses a family of new pharmaceutical
excipients consisting of particles with a matrix of thin lamellae
that form a porous meshwork. Differently produced FCC showed
different pore types, namely the core voids that were surrounded
by stratum voids. Upon compaction, numerous changes are
observed, both on the microscopic and mesoscopic (particulate)
size range. In particular, FCC can be compacted into tablets with
high tensile strength at compressive pressures which are much
lower than those needed for the compaction of other excipients
such as mannitol or cellulose. This phenomenon can be attributed
to interlocking of surface lamellae between FCC particles. We
assume that the lamellar structure, and hence, the larger surface
area of FCC, is the main origin of these extraordinary properties.
Inter- and intraparticle voids can accommodate drugs of
interest such as paracetamol, offering interesting opportunities
for drug delivery. The porosity of FCC containing tablets subjected
to a compressive pressure of 100 MPa can reach values up to 60%,
whereas tablets containing cellulose or mannitol only have 20%
void volume.
FCC granules can be prepared by roller compaction or high
shear granulation. Roller compaction had no significant impact on
FCC tablet properties. Due to the high porosity, water penetrates
FCC rapidly by capillary forces, leading to a fast disintegration of
FCC tablets. This phenomenon can be exploited for the preparation
of orally dispersible tablets (Stirnimann et al., 2013). Although FCC
is a brittle substance, it showed mechanical properties (e.g. tensile
strength and porosity) equal or superior to those of plastically
deforming microcrystalline cellulose. We therefore anticipate FCC
to have a considerable potential in pharmaceutical research and
development.
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Roller compaction of functionalized calcium carbonate (FCC): 
improved powder properties at retained compactibility 
 
Abstract  
Purpose: The aim of the present study was to investigate the influence of roller compaction on the 
tableting properties of functionalized calcium carbonate (FCC) and its formulations.    
Methods: We compared FCC with Avicel as well as mixtures of these excipients in combination with 
paracetamol at drug loads of 0%, 24.75%, 49.50%, 74.25%, and 100% (w/w). Granules were roller-
compacted at 5 bar and 20 bar roll pressures. Compactibility was analyzed after tableting the granules at 
a compressive pressure of 6 MPa to 500 MPa. 
Results: FCC granules showed better flowability than Avicel granules. In the low pressure range 
(< 100 MPa), the loss of compactibility due to dry granulation was marginal for FCC. Over 100 MPa 
compressive pressure, dry granulation increased the compressibility of FCC granules in comparison to 
FCC powder. Mixtures with FCC and paracetamol yielded significantly higher tensile strengths over the 
whole pressure range than mixtures with Avicel and paracetamol (except for the formulation with 74.25% 
(w/w) drug load). Mercury porosimetry showed that intraparticle pore structure of the FCC powder within 
the granules was affected neither by the roller compaction process nor by the subsequent tableting 
process.    
Conclusions: This study showed that FCC is a suitable excipient for dry granulation due to easily-
producible ribbons and retained compactibiliy properties after roller compaction.  
 
Keywords  
Dry granulation, tensile strength, functionalized calcium carbonate (FCC), lamellar structure, high 
surface, flowability, pore structure 
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1. Introduction 
Roller compaction is a dry granulation method where agglomerates (ribbons) are formed. The transition 
from powder particles to a larger granulate entity reduces interparticle cohesiveness, resulting in a better 
flowability and improved uniformity of content. Roller compaction is a continuous process. It can handle 
high drug loading and prevents segregation. The fact that no liquid has to be added makes roller 
compaction a convenient method to granulate moisture and heat sensitive drugs. During the roller 
compaction process, particles bind to each other due to surface contacts. In the feeding zone of a roller 
compactor the particles rearrange before deformation, fragmentation, and bonding takes place (1). The 
type of bonding between particles, namely due to van der Waals interaction, e.g. interlocking forces and 
solid bridges, depends on the material properties (compressibility, deformation, fragmentation) (2). 
Drawbacks of conventional roller compaction processes are reduced compactibility and dissolution 
issues. Compactibility can be described by plotting the crushing strength (nowadays crushing strength is 
often replaced by tensile strength) as a function of compressive pressures (3,4). Compactibility provides 
information about the bonding properties of a material (5). Malkowska and Khan observed for the first 
time that roller compaction has a negative influence on the tablet tensile strength in comparison to direct 
compression (6). Sun and Himmelspach studied the mechanism for the loss of compactibility of 
microcrystalline cellulose (MCC). They found that granule size enlargement was responsible for reduced 
compactibility of MCC due to decreased surface area (7). Patel et al. showed that the loss of 
compactibility for MCC is a combination of the work-hardening phenomenon and size enlargement, 
whereas the granule-hardening affects tensile strength more than granule size enlargement (8). Bultman 
showed that multiple compaction of pure microcrystalline cellulose could reduce the amount of fines, 
increases flow properties and improves size distribution. Furthermore, he found that each compression 
step irreversibly reduces some of the limited binding potential of MCC (9). In general, fine particles show 
better compactibility than coarse particles depending also on the size distribution characteristics of the 
particles. Nevertheless, the compaction properties of brittle materials are less affected by the particle 
size of the granules compared to plastic materials. Plastic materials characteristically display a reduced 
surface area available for bonding. During the fragmentation of brittle materials new surfaces are 
created, serving as new bonding regions. This effect was shown by Wu and Sun. They performed 
studies on brittle granules made of spray-dried lactose monohydrate, anhydrous dibasic calcium 
phosphate, and mannitol. Their study concluded that compactibility of brittle granules prepared with roller 
compaction are insensitive to granule size (10).  
The effect of available surface for bonding is one of the most important factors for roller compacted 
ribbons, i.e. granule strength. Based on this main assumption, functionalized calcium carbonate (FCC) 
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as a material with highly developed and large specific surface (> 60 m²/g) is a material of interest for 
formulations developed with roller compactors.   
The petal structure of FCC surface was described by Stirnimann et al. (11) and implies that the lamellae 
are very thin (in the range of a few nanometers), which assumes potentially high flexibility, similar to that 
displayed by nacre (12); hence, an ability to maintain a high contact surface after initial mechanical 
deformation (roller compaction). Therefore, it is possible to assume that FCC will not lose its high 
compactibility properties after initial deformation under roller compaction. 
The aim of the present study was to investigate the influence of roller compaction on the tableting 
properties of FCC and formulations containing it. 
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2. Materials and methods 
2.1 Materials 
Functionalized calcium carbonate (FCC), type S02, (VP-OM2501 S02, Omya International AG, 
Switzerland) was compared to microcrystalline cellulose (Avicel® PH 102, FMC BioPolymer, Ireland). 
Paracetamol was chosen as a model drug (Acetaminophen USP / Paracetamol Ph Eur Powder, 
Mallinckrodt, USA) used in the role of active pharmaceutical ingredient. Sodium stearyl fumarate (SSF, 
LubriSanaq®, Pharmatrans Sanaq AG, Switzerland) was used as an inner phase lubricant during roller 
compaction, whereas magnesium stearate (MgSt, Sandoz, Switzerland) was used as an outer phase 
lubricant during tableting. Mercury (Sigma-Aldrich, Germany) was used for pressure intrusion 
porosimetry measurements as a non-wetting liquid. 
 
2.2 Methods 
2.2.1 Roller compaction and milling 
Before roller compaction, each powder was sieved through a 1 000 µm sieve to destroy agglomerates. 
Excipients were blended with paracetamol to obtain relative paracetamol contents of 24.75% (w/w), 
49.50% (w/w), 74.25% (w/w), and 99% (w/w). In addition, reference formulations without paracetamol 
were prepared. For comparative reasons, all the formulations contained 1% of sodium stearyl fumarate 
as an inner lubricant. The lubrication was necessary for the roller compaction process of paracetamol, 
due to sticking problems. We mixed the powders for 10 min in a tumbling mixer (Turbula T2C, Willy A. 
Bachofen AG, Switzerland) at 32 rpm. Granulation was performed with a Fitzpatrick® Chilsonator IR220 
roller compactor (The Fitzpatrick Company, USA). Pressure was set either to 5 bar or to 20 bar. The 
feed rate and the roll speed were adjusted to obtain a ribbon thickness of 0.6 mm. After roller 
compaction the ribbons were milled with a FitzMill® L1A (The Fitzpatrick Company, USA) at 500 rpm.  
 
2.2.2 Screening 
A screening was performed to find the formulations of interest. For each formulation 10 g of the 
respective ribbon were put on a sieve with 500 µm mesh size. The sieve was shaken for 10 minutes with 
the help of a vibrating sieve tower (Vibro Retsch, Switzerland) at a shaking displacement of 1.5 mm. The 
remaining fraction (RF) was calculated with the help of equation (1): 
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  (1) 
where mtot is the total mass applied initially on the sieve (g) and mres is the residual amount on the sieve 
(g) after 10 minutes of shaking.  
Formulations with a remaining fraction of more than 60% were considered as robust enough for the 
tableting process.  
 
2.2.3 Granule analysis 
To determine the fine fraction obtained with the roller compaction process, the product of the roller 
compaction process (ribbons including fines) was collected, weighed (mtot), and afterwards sieved 
through a sieve with 180 µm mesh size as described in section 2.2.2.  
The fine fraction (FF) was calculated with the help of equation (2): 
    
               
    
 (2) 
where mtot is the mass applied initially on the sieve (g) and mres is the residual amount on the sieve (g) 
after 10 minutes of shaking.  
The particle size distribution analysis was performed with a vibrating sieve tower. The sieving tower was 
shaken for 10 minutes at a shaking displacement of 1.5 mm. We used steel wire screens (Vibro Retsch, 
Germany) with mesh sizes of 180 µm, 250 µm, 355 µm, 500 µm, and 710 µm. The amount of powder 
remaining on each sieve was weighed. Granules with a size of less than 180 µm or more than 710 µm 
were excluded.  
Flowability as well as bulk and tapped density were measured for selected granular fractions according 
to Ph Eur (13). For the flowability measurement a Mettler PM460 balance (Mettler Toledo, Switzerland) 
was used. Three different openings (5 mm, 7 mm, and 9 mm) were chosen. Bulk and tapped density 
were measured with a STAV 2003 volumeter (J. Engelsmann, Germany). The Hausner ratio (tapped 
density/bulk density) was calculated according to Ph Eur (13). 
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2.2.4 Tablet preparation 
For the tablet preparation, all granules with a size between 180 µm and 710 µm (14) were used. The 
granules were dried overnight (12-15 h) under nitrogen flow in a vacuum drying cabinet of type KVTS 11 
(Salvis, Switzerland) before they were mixed in a tumbling mixer (Turbula T2C, Willy A. Bachofen AG, 
Switzerland) for 10 minutes at 32 rpm. The granules were compressed with a 10 mm round, flat tooling, 
using a Styl’One 105 ml tablet press (Medel’Pharm, France). The tablet press was instrumented with the 
Analis software version 2.01 (Medel’Pharm, France). During compaction, tablet volume was kept 
constant at the lowest compressive pressure due to highly variable porosities of the raw materials. The 
punch gap was adjusted for each formulation to obtain a tablet height of 6 mm at a compressive 
pressure of 6.37 MPa (0.50 kN). The punch gap was kept constant over the whole compressive pressure 
range for each formulation. The formulations were compacted in triplicate at 10 different compressive 
pressures, ranging from 6 MPa to 500 MPa. If lamination occurred below 500 MPa, further increase of 
the compressive pressure was halted. Punches and die were manually lubricated with magnesium 
stearate. Tablets were compressed at minimum possible dwell time by setting the rise and fall of the 
lower punch to 750 ms and the “maintain” phase to 0 ms. 
Temperature and relative humidity during tablet preparation and analysis were between 22.3°C and 
25.9°C, and 28.5% and 50.0%, respectively.  
 
2.2.5 Tablet analysis (weight, diameter, height, crushing force, tensile strength, and friability) 
Tablet weight, diameter, height, and crushing force were measured in triplicate directly after tablet 
compression. Weight was determined with a Delta Range AX204 balance (Mettler Toledo, Switzerland).  
Diameter and height were measured with a micrometer screw of type CD-15CPX (Mitutoyo, Japan). 
Crushing forces below 400 N were measured with a tablet hardness tester (8M, Dr. Schleuniger 
Pharmatron, Switzerland) at a speed of impact of 1 mm/s. Harder tablets (> 400 N) were tested with the 
Styl’One tablet press (Medel’Pharm, France) as described in the previous study (11).  
Tensile strength was calculated with equation (3): 
   
  
   
 (3) 
where σt is the radial tensile strength (MPa), F is the crushing force (N), d is the tablet diameter (mm), 
and h is the tablet thickness (mm). 
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Friability of tablets compressed at 100 MPa was measured with a drum (Erweka, Germany) according to 
Ph Eur (13).  
 
2.2.6 Heckel and modified Heckel equation 
With the help of the software OriginPro version 8.5 (OriginLab Corporation, USA), the Heckel expression 
(15,16) was fitted according to equation (4):  
   
 
   
       (4) 
where  is the tablet density (g/cm3), k is the Heckel parameter (MPa-1),  is the compressive pressure 
(MPa), and A is a constant. We considered 4 data points between 50 MPa and 200 MPa for the Heckel 
analysis.  
The density () was calculated according to equation (5): 
  
        
     
 (5) 
where m is the tablet mass (g), r is the tablet radius (cm), h is the tablet height (cm), and true is the true 
density of the skeletal forming substance within the porous tablet (g/cm3).   
Mean yield pressure (σy, MPa) was calculated with equation (6): 
   
 
 
 (6) 
where k is the Heckel parameter (MPa-1).   
The modified Heckel equation (17) was fitted according to equation (7): 
  
 
 
                 
   
     
   (7) 
where σ is the compressive pressure (MPa), C is a constant (MPa-1), rc is the relative critical density, 
and  is the relative density of the tablet. For the modified Heckel analysis 6 data points between 5 MPa 
and 200 MPa were considered.   
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2.2.7 Pore size distribution in tablets 
To measure the pore size distribution, tablets were prepared as described in section 2.2.4. The analysis 
was performed with an Auto Pore IV 9500 mercury porosimeter (Micromeritics, USA). Low-pressure and 
high-pressure mercury intrusion ranged from 3.59 kPa to 206.64 kPa and from 206.78 kPa to 
206.78 MPa, respectively. Equilibration time was set to 10 s over the whole pressure range.  
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3. Results and Discussion 
3.1 Screening 
A screening process was aimed to find the formulations of interest for further studies, namely 
compaction studies. For tableting, the granules have to show certain rigidity for further processing. In our 
setup, the fine fraction (< 500 µm) gave us a hint of the rigidity of a ribbon. A screening with 18 
formulations yielded 10 formulations of interest because they all showed a remaining fraction (> 500 µm) 
of more than 60% (w/w). This means that only 40% of the solid (in the form of ribbons) was collapsed 
into fines with a size of less than 500 µm after shaking for 10 minutes. 
FCC with SSF showed a very high remaining fraction (approx. 90%) during roller compaction, 
independent of the applied roll pressure (the value for the remaining fraction for granules prepared at 
20 bar is within the standard deviation of the value for 5 bar). This result showed that rigid ribbons made 
of FCC could be roller-compacted even at low pressures (5 bar). In general we observed higher 
remaining fractions; thus, more rigid ribbons for the powder blends that were roller compacted at higher 
pressure (20 bar). This effect was more pronounced for mixtures containing Avicel. We assumed that the 
particles were packed denser at higher pressures, resulting in stronger interparticle bonds due to more 
surface contacts and therefore, more rigid ribbons. Avicel with SSF admixtures processed at 5 bar roll 
pressure showed only 10% (w/w) remaining fraction, which is a sign of very fragile ribbon. We assumed 
that, in contrast to FCC, the pressure of 5 bar was not enough for Avicel to form a sufficient number of 
interparticle bonds. At 20 bar the Avicel and SSF powder blend did not enter the compression region and 
resulted in the failure within the feeding zone of the roller compactor.  
For the drug loads over 50% (w/w), the remaining fraction was inferior and, therefore, the ribbons were 
weakest. It is well known, that paracetamol crystals are brittle (18,19); however, during tableting 
paracetamol compensates mechanical stress by elastic recovery (20–24). We assume that the elastic 
recovery of paracetamol is responsible for weakening the ribbons at higher paracetamol contents. 
 
3.2 Granule properties 
Table 1 shows the fine fraction during roller compaction for all the formulations of interest. Again we 
supposed a negative influence of paracetamol on the rigidity of Avicel ribbons. We assumed that Avicel 
was not able to compensate the effect of elastic recovery caused by paracetamol, especially at high drug 
loads. FCC mixtures showed a 50% reduction of the fine fraction after increasing compressive pressure 
during roller compaction from 5 bar to 20 bar. We consider that the particles moved closer together at 
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higher pressure and formed a higher number of interparticle bonds. Comparable to Avicel, we observed 
a trend for higher fine fractions for FCC by increasing the amount of paracetamol in the mixtures. The 
amount of fines could be reduced by further process optimization, for example by changing the profile of 
the rolls.  
By employing roller compaction of FCC it was possible to increase the flowability of FCC significantly 
and, hence, overcome the limitations of the poor flowability of FCC in powder form (11,24). With respect 
to flowability, table 1 shows that granules obtained at 5 bar were significantly slower flowing than the 
ones obtained at 20 bar. A possible reason was the denser packing at 20 bar and a smoother surface 
with less outstanding lamellae (reduced cohesiveness). FCC in combination with SSF showed fastest 
flowability (8.51 g/s through an opening of 9 mm). At the same drug load and at the same compressive 
pressure during roller compaction, the FCC mixtures were always faster than the Avicel mixtures. 
Possible reasons are different particle shapes, different particle sizes, different particle size distributions, 
and a smoother surface texture. The particle size distribution of Avicel showed that the mixture mainly 
contained fines and very coarse granules (data not shown). We assumed that this distribution was 
responsible for slower flow, especially due to the fines which hindered the flowability due to increased 
cohesiveness. Furthermore, we assumed that the high mass fraction of coarse particles in the FCC 
mixtures accelerated the flowability because they were heavier than the smaller ones. Our observations 
are in agreement with Liu et al., who showed better flowability for powder with narrow particle size 
distribution. Among powders with narrow size distribution they also observed a faster flow for larger 
particles (26). For the openings between 9 mm to 7 mm the flow rate was reduced by factors ranging 
from 1.7 to 1.8. From the opening 7 mm to 5 mm the speed of the particles was reduced by the factors 
2.4 to 2.6.  
Table 1 shows that 5 bar compacted granules showed lower densities compared to granules compacted 
at 20 bar due to a looser packing derived from the lower applied pressure during roller compaction. In 
general, densities for FCC mixtures were always higher compared to Avicel mixtures. The Hausner ratio 
lay between 1.04 and 1.11 for all the mixtures, meaning that the consolidation during tapping was 
minimal. It is noted that the Hausner ratio became smaller by increasing the amount of paracetamol. A 
possible reason is the structure and smooth surface texture of paracetamol, which did not allow 
rearrangement after the initial packing. Lamellae of FCC and the fibers of Avicel can interlock and 
prevent the particles from forming a dense packing. The higher the amount of paracetamol in the 
formulation, the smaller the interlocking effects of Avicel and FCC, hence the reduction of the Hausner 
ratio.  
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 3.3 Tablet properties 
Table 1 presents the resulting tablet weights for different formulations. Granules roller-compacted at 
5 bar yielded lighter tablets than the granules at 20 bar due to less densification during roller compaction. 
Among paracetamol mixtures processed at 20 bar, the FCC-paracetamol mixtures produced heavier 
tablets compared to Avicel-paracetamol mixtures at the same drug-excipient ratio due to higher FCC 
bulk density (ca. 0.64 g/cm3) compared to Avicel (ca. 0.57 g/cm3).  
 
Table 1: Granule and tablet properties. “x” is indicating that no tablet was obtained at 100 MPa (not stable enough / 
lamination). “Fail” means that the sample failed the test due to broken tablets. 
 
Table 1 shows that the tablet friability was considerably lower for FCC-paracetamol mixtures than for 
Avicel–paracetamol blends. Among the Avicel formulations, friability could only be measured for the 
tablets with 49.50% drug load. We assumed that the elastic properties of paracetamol could not be 
compensated by Avicel and, as a result, the tablets did not show enough physical strength to pass the 
friability test. Friability values for FCC with admixtures of SSF (independent of pressure applied during 
roller compaction) and FCC in combination with a low drug load (roller compacted at 5 bar) were below 
1%. Interestingly, the FCC granules obtained at 5 bar produced tablets with significantly lower friability 
than the ones compressed at 20 bar. This phenomenon is explained in Figure 1.  
Mixtures 
 
 
Fine 
fraction 
(%) 
Flowability (g/s) Bulk 
density 
(g/ml) 
Tapped 
density 
(g/ml) 
Hausner 
ratio 
 
Tablet 
weight 
(mg) 
Friability 
at 100 
MPa (%) 5 mm 7 mm 9 mm 
99% FCC + 1% SSF_5bar 12 
5.10 ± 
0.05 
2.93 ± 
0.06 
1.19 ± 
0.01 
0.53 0.56 1.06 350.1 ± 2.6 0.24 
99% FCC + 1% SSF_20bar 6 
8.51 ± 
0.02 
4.72 ± 
0.01 
1.91 ± 
0.01 
0.79 0.82 1.04 462.6 ± 4.2 0.73 
74.25% FCC + 24.75% P + 1% SSF_5bar 21 
5.52 ± 
0.04 
3.09 ± 
0.00 
1.27 ± 
0.02 
0.55 0.58 1.06 371.4 ± 2.9 0.56 
74.25% FCC + 24.75% P + 1% SSF_20bar 10 
7.54 ± 
0.02 
4.19 ± 
0.01 
1.68 ± 
0.02 
0.66 0.73 1.11 436.7 ± 3.7 1.13 
49.50% FCC + 49.50% P + 1% SSF_20bar 30 
7.02 ± 
0.05 
3.85 ± 
0.02 
1.56 ± 
0.01 
0.63 0.68 1.07 442.0 ± 4.3 1.76 
24.75% FCC + 74.25% P + 1% SSF_20bar 29 
7.17 ± 
0.02 
3.96 ± 
0.00 
1.58 ± 
0.02 
0.64 0.68 1.05 435.2 ± 2.7 x 
74.25% Avicel + 24.75% P + 1% SSF_20bar 8 
5.98 ± 
0.04 
3.44 ± 
0.02 
1.41 ± 
0.00 
0.55 0.60 1.10 375.6 ± 3.4 Fail 
49.50% Avicel + 49.50% P + 1% SSF_20bar 17 
6.13 ± 
0.02 
3.41 ± 
0.01 
1.33 ± 
0.01 
0.56 0.61 1.09 383.5 ± 6.5 6.71 
24.75% Avicel + 74.25% P + 1% SSF_20bar 45 
6.19 ± 
0.02 
3.54 ± 
0.03 
1.39 ± 
0.02 
0.61 0.64 1.04 394.9 ± 4.2 Fail 
99% P + 1% SSF_20bar 55 
6.39 ± 
0.06 
3.57 ± 
0.02 
1.49 ± 
0.01 
0.63 0.68 1.07 448.7 ± 2.1 x 
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Figure 1 shows the tablet tensile strengths as a function of compressive pressures. Up to 250 MPa 
pressure, the tensile strength increased almost linearly for all formulations at increasing compressive 
pressure. At the same compressive pressure within the low pressure range (enlargement inside Figure 
1), the tablet tensile strength was higher for compacts prepared from powders, followed by compacts 
from granules roller-compacted at 5 bar, and, finally, tablets made from granules compacted at 20 bar. In 
other words, the friability is dependent on the tablet tensile strength, which is a function of surface 
available for contacts. The higher the pressure during roller compaction, the denser is the packing of the 
particles and the higher the loss of surface area.  
 
Figure 1: Tensile strength of FCC based tablet formulations as a function of compressive pressure. Tablets contained 
varying amounts of paracetamol (P) and were prepared using FCC powder (dotted lines) or FCC granules obtained by roller 
compaction at 5 bar (gray solid line) or 20 bar (black solid line). All granules contained 1% sodium stearyl fumarate. Values are 
means ± SD of n=3 experiments. Insert: magnification of the low compressive pressure range up to 100 MPa  
 
However, this statement is not entirely supported by the tensile strength results at higher compressive 
pressures (> 200 MPa), where the tensile strengths of tablets made from 5 bar granules were higher 
than the ones made from powder. This can be explained by the fact that SSF admixture to the FCC 
reduces the lamellar contact area by forming contact obstacles.  
At very high pressures (~ 400 MPa), tensile strength of tablets made of 5 bar granules and 20 bar 
granules were comparable. At such stresses, the granules (and also the particles within a granule) could 
break and, hence, provide additional surface area for bond-making contacts (12). The effect of 
increasing tensile strength due to particle breaking, we already observed in a previous study (11). For 
granules compressed at 20 bar, more compressive pressure was necessary to break the particles, in 
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contrast to granules obtained at 5 bar. In contrast to tablets made of powder blends, the risk for tablet 
lamination was reduced at higher compressive pressures using FCC granules. This observation can be 
best explained by the fact that during the roller compaction process, a packing and densification of FCC 
particles takes place, which facilitate the rearrangement and packing of the granules later during 
tableting in contrast to the bulky powder. In such a case the roller-compaction process acts as a pre-
compression stage during tableting for FCC-based formulations.  
The positive effect of high specific surface on the stability of tablets is supported by tablet tensile 
strength results for FCC-paracetamol and Avicel-paracetamol mixtures. 
Figure 2 shows the tensile strength as a function of compressive pressure for paracetamol mixtures with 
FCC and Avicel. The mixtures with FCC reached much higher tensile strength values than the mixtures 
of Avicel and paracetamol, except the formulation with 24.75% FCC. For the mixture with 74.25% 
paracetamol, FCC reached the maximal tensile strength (0.16 MPa) already at 50 MPa. The Avicel 
formulation with the same drug load reached this value after 150 MPa compressive pressure was 
applied. The Avicel formulation with 74.25% drug load reached a 3.4 times higher tensile strength than 
FCC in combination with paracetamol, but needed 10 times more pressure to reach this value. We 
suppose that the lamellar surface of FCC is responsible for the high values of tensile strength even at 
lower pressures. At higher drug load, FCC showed superior properties compared to Avicel, especially in 
the lower pressure range. Paracetamol is known to be a difficult substance for tableting due to the fact 
that it compensates mechanical stress by elastic recovery (20–24). Therefore, we assume similar 
behavior as shown for FCC in this study not only for combinations with paracetamol but also in 
combination with other drugs. 
 
 
 
Figure 2: Compaction of granules 
containing mixtures of paracetamol (P) and 
FCC or Avicel. Comparison of tensile 
strength of tablets as a function of 
compressive pressure. All formulations were 
granulated at 20 bar and contained 1% 
sodium stearyl fumarate. Values are means ± 
SD of n=3 experiments. 
 
Table 2 shows the values for the Heckel and modified Heckel analysis. The higher the pressures during 
roller compaction, the lower the values for the Heckel parameter (k) for the tablets. A low value for “k” 
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indicates higher pressure is needed to obtain a stable tablet at the same tensile strength. The values for 
relative critical density (ρrc), i.e. the tablet density at which the stable compacts can be first formed, 
supported the results from the Heckel analysis. The differences between the powder and 5 bar granules 
were much smaller than the differences between the 5 and 20 bar granules. 
 
Table 2: Heckel and modified Heckel parameters. The values for mixtures containing Avicel and paracetamol are not shown 
because some values were missing for the fitting in the chosen pressure range. *) indicates that these data were already 
pubished (11) 
Substances Heckel equation   Modified Heckel equation   
  
k(10
-3 
MPa
-1
) 
± SD A ± SD σy (MPa) R
2
   
C(10
-3
 MPa
-1
) 
± SD rc ± SD R
2
 
100% FCC powder 2.61 ± 0.15 0.44 ± 0.02 383 0.990 
 
1.006 ± 0.064 0.160 ± 0.014 0.998004 
99% FCC + 1%SSF_5bar 2.43 ± 0.15 0.43 ± 0.02 412 0.989 
 
0.767 ± 0.031 0.193 ± 0.008 0.999036 
99% FCC + 1%SSF_20bar 2.13 ± 0.08 0.55 ± 0.01 469 0.996 
 
0.525 ± 0.029 0.303 ± 0.008 0.998171 
75% FCC + 25% P powder *
) 
2.97 ± 0.28 0.62 ± 0.04 336 0.974   1.051 ± 0.122 0.280 ± 0.024 0.994061 
74.25% FCC + 24.75% P +1% SSF_5bar 2.82 ± 0.13 0.58 ± 0.02 354 0.994 
 
0.891 ± 0.021 0.285 ± 0.004 0.999704 
74.25% FCC + 24.75% P +1% SSF_20bar 2.29 ± 0.09 0.69 ± 0.01 437 0.995 
 
0.549 ± 0.018 0.380 ± 0.004 0.999448 
50% FCC + 50% P powder *
) 
3.23 ± 0.32 0.83 ± 0.04 309 0.972   0.985 ± 0.127 0.406 ± 0.023 0.993015 
49.5% FCC + 49.5% P +1% SSF_20bar 2.46 ± 0.21 0.95 ± 0.03 406 0.979 
 
0.507 ± 0.043 0.509 ± 0.010 0.996791 
25% FCC + 25% P powder *
) 
3.19 ± 0.42 1.13 ± 0.05 313 0.951   0.708 ± 0.137 0.562 ± 0.025 0.98597 
24.75% FCC + 74.25% P +1% SSF_20bar nd nd nd nd   nd nd nd 
 
 
3.4 Mercury porosimetry 
Figure 3 shows a mercury porosimetry plot of the pore size distributions of FCC tablets made with 
powder and granulates. The tablets were compressed at three different compressive pressures. By 
increasing the compressive pressure, the characteristic peaks were shifted to smaller pore diameters 
(Figure 3) as a result of FCC densification and collapsing of lamellae on the surface of particles. The 
plots of tablets compressed at the same compressive pressure were almost congruent, for all types of 
the primary material (powder or granules). The only noted difference is the higher pore volume of 
granules at larger pore diameters compared to powders. We assumed that the voids between granules 
were larger after rearrangement and compression than the voids between powder particles. The effect 
was more pronounced at lower compressive pressures due to a lesser densification and, thus, to a 
greater likelihood of void volume preservation. The intraparticular structure of FCC (pores with a 
diameter of less than 0.02 µm) was affected neither by the roller compaction process, nor by tableting. 
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Figure 3: Porosity of FCC after compaction. Comparison of compacted FCC powder (P-FCC) or FCC granules (G-FCC). G-
FCC was granulated at 5 bar. Mercury porosimetry was used to analyze the pore size distribution of FCC at increasing 
compaction pressures. Values are means of n=2 measurements.  
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Conclusion 
Roller compaction of FCC revealed rigid ribbons at a low fine fraction, even at low pressures during roller 
compaction. The resulting granules made of FCC and a model drug showed better flowabilities than 
Avicel based formulations. We could show that the loss of compressibility for FCC in the low pressure 
range below 100 MPa was marginal. Over 100 MPa compressive pressure, which is a commonly used 
pressure for industrial production, the granulation had a significant positive effect on the compressibility 
compared to tablets made of FCC powder only. We conclude that pre-densification during roller 
compaction led to a more homogenous stress distribution during tableting with granules. In addition, 
tablets composed of granulated FCC and the model drug showed significantly higher tensile strengths 
over the whole pressure range than Avicel based formulations. Thus, granulated formulations of FCC 
have superior properties with respect to flowability and compressiblity as compared to Avicel or non-
granulated FCC formulations.  
The intraparticular structure of FCC, i.e. mesoporous voids with a pore diameter in the range of 2 to 50 
nm, was affected neither by roller compaction, nor by tableting. This result indicates that neither the 
flexible lamellar structure nor the high surface area of FCC are affected by roller compaction. We 
conclude that granulation does not interfere with drug loading of FCC.  
FCC powder has a poor flowability limiting its use in pharmaceutical production. This problem can be 
overcome by dry granulation using roller compaction. This offers the possibility to process the novel 
pharmaceutical excipient FCC on high speed rotary tablet presses and to make it accessible for 
industrial large scale production. 
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Analysis of power consumption profiles during wet granulation 
as a function of particle configuration 
 
Abstract 
Purpose: The aim of this study was to investigate the appearance of liquid bridges of different 
configurations, which result in stepwise increase of the power consumption profile during a wet 
granulation.  
Methods: Spherical Fujicalin particles were used as model particles. Fujicalin particles were granulated 
in a high-shear mixer by the addition of three different binder concentrations (10%, 15%, and 20% 
Kollidon 25). The experimentally obtained results were compared with the calculated wetting ratios at 
different granulation phases.  
Results: It was possible to interpret the stepwise increase of the torque signal in a typical power 
consumption profile by different geometrical arrangements of the spherical particles depending on the 
liquid content. The calculated regions of bridge configuration changes were detected on the experimental 
power consumption profiles.   
Conclusions: Our findings confirm that, during liquid addition to a powder bed, the critical concentration 
of liquid is influencing not the powder system as a whole (e.g., classical single percolation concentration 
or percolation threshold) but first changes granular composition, followed by alteration of overall system 
properties. The proposed new method to determine the bridge configuration changes will be helpful for 
further understanding of the granulation process and for calculating potential critical phases during large 
scale trials. 
 
Keywords  
Excipients, contact angle, granulation, powder technology, mathematical model, liquid bridge 
morphologies, high-shear mixer, granulation phases 
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1. Introduction 
1.1 Background 
Wet granulation in a high-shear mixer is a widely-used pharmaceutical unit operation to produce 
granules for further processing, such as tableting. Granulation is a critical process step in pharmaceutical 
research, development, and production.  
In the past, there were several attempts made to control the agglomeration process in a high-shear 
mixer with the help of power consumption recording. It is possible to monitor during high-shear 
granulation the mixer power consumption as a function of the added granulation liquid 1. In such case, 
the granulation liquid has to be added slowly and continuously to the powder bed that is stirred by an 
impeller and a chopper. The adhesion force between the particles during the agglomeration process 
cannot be measured directly; however, it can be assessed by the power consumption analysis. Figure 1 
shows that the granulation process can be divided into five phases according to Leuenberger. In a first 
phase, an initial and slow wetting of the powder mixture takes place and the internal micro-pores are 
filled with the binder liquid. In phase II, the first pendular bridges between particles are formed and the 
powder particles agglomerate. Further agglomeration, simultaneous kneading, and compacting of the 
powder occur in phase III. This phase can be characterized by a balance between liquid bridges in 
pendular and funicular states. This is the phase of interest for pharmaceutical applications as the 
granules obtained within this phase are mostly desired. Afterwards, in phase IV and V, an irreversible, or 
catastrophic, over-wetting takes place. The system changes into a suspension due to the excess of 
water 1–3. The end point of the granulation depends on the formulation, the process parameters, the 
desired final granule size distribution, and so on. Detection of the granulation end-point remains a very 
complex, yet very important task for process engineers.  
 
 
Figure 1: Schematic representation of the 
different stages during wet granulation in a 
high-shear mixer. Dry state (phase I), pendular 
state (phase II & III, individual liquid bridges 
(black) are formed at the contact points of the 
particles (grey)), funicular state (phase II-III, 
individual liquid bridges start to merge, more than 
two particles can be linked), capillary state (phase 
IV, cavities between the particles are fully 
saturated with liquid), and droplet state (phase V, 
particles are suspended in the liquid) 
1,2
. 
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Scheel et al. have shown that within a wetting ratio (W) of 1-16% (v/v), defined as liquid volume divided 
by the total sample volume, the amount of liquid added to a sand pile has almost no influence on the 
mechanical properties of the pile 4,5. At the same time it could be shown that above W ~ 2.5% (v/v) and a 
half-filling angle (, Figure 2) beyond π/6 (=30°C) the cohesive forces between the particles do not grow 
anymore (because the pressure inside the liquid levels off) and as a result the capillary bridges (pendular 
state) start to merge, i.e. following a transition to a funicular state. With the help of x-ray 
microtomography it was possible to show that by increasing the liquid content, the liquid bridges 
(capillary bridges) merge first to trimers, then to pentamers and finally to filled tetrahedras until a wet 
cluster is formed that finally turns into a slurry 4–7. The x-ray microtomography experiments on the wet 
sand pile for spherical equally-sized particles show that above W ~ 11% (v/v) almost all particles in the 
powder bed are connected by one large, percolating cluster that contains about 90% of the liquid 5. 
Interestingly, the wetting ratio (W) during high-shear granulation is often around 10% (v/v) for initial start 
of phase II, as reported previously 8,9. 
 
1.2 Theoretical considerations for new analysis of power consumption profile 
As it was shown in the work of Scheel et al.5, the bridge geometries are not changing monotonously with 
increase of moisture content for a simple, equisized spherical test system. This finding is very important 
to reconsider classical view on liquid bridge formation between two or more solid spheres, if those 
spheres are part of very large population. Interestingly, the transition from one bridge geometry to 
another is not happening continuously for systems with large number of interacting particles.  
Scheel et al.5 have experimentally determined the prevalent configurations at different wetting ranges, 
i.e. bi-, tri-, tetra-, penta- and heptamers. Thus, existence of major agglomerate configurations at certain 
liquid concentration range assumes that individual volume of each bridge configuration stays same. In 
the same work of Scheel et al., the bridge volumes of different configurations were determined 
experimentally (in voxels) for glass beads with the help of X-ray imaging. We summarized the number of 
voxels necessary to build each bridge configuration and used them to calculate the volume multiplication 
factor: capillary bridge (CB) is 1; trimer is 4; pentamer is 8; tetrahedra is 12 unit volumes.  
The main theoretical assumption of this study is that same geometrical transitions could be observed on 
a power consumption profile during wet granulation. In such case it is possible to calculate the amounts 
of liquid added where the bridge configuration change is expected, using the single bridge volume and 
the corresponding multiplication factor. 
If the liquid addition rate is fixed during the granulation process, the time to transition can be calculated. 
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In order to carry out the necessary calculations we assumed the powder bed is composed of spherical, 
equisized particles of non-soluble material with hydrophilic surface. We attempted to calculate the single 
capillary bridge volume and liquid necessary to reach specific agglomerate configuration for 3 different 
concentrations of the binder polymers. 
Kepler conjecture 
The closest packing of equally sized spheres in a three-dimensional space can reach a maximum 
density of 0.74048 10,11. If the spheres are randomly packed, density decreases to around 0.64 12. 
However, this packing efficiency is valid for spherical, equally-sized particles only. Another important 
parameter is the size of the particles used. For highly poly-disperse powder the packing efficiency is 
heavily changing and is related to Apollonian packing problem 13. In order to leverage such effects the 
application of single-size fractions of the powders is advantageous. 
Capillary liquid bridge 
Calculation of a liquid bridge volume for different particle geometries and materials in contact is well 
documented 14,15. Figure 2 shows a schematic representation of two particles connected with a liquid 
bridge. 
In the following steps the calculation of a liquid bridge volume between two particles is shown. The radii 
of the liquid bridge curvature (1 and 2) can be calculated according to the geometrical analysis by 
equation 1 and 2: 
   
              
         
, (1) 
                          , (2) 
where si indicates half of the distance from one particle (i) to another (h), ri is the radius of the particle (i), 
i is half of the filling angle of particle (i) in radians, and  is the contact angle in radians between the 
particle and the binder liquid.  
 
 
Figure 2: Schematic representation of a liquid bridge between two 
particles. In our model, the distance h between two particles (i) with radius ri 
was zero. The half-filling angle i was 15 degrees 
16
, the contact angle  was 
determined experimentally, and 1 and 2 are the radii of the liquid bridge 
curvature that can be calculated 
15
. 
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The volume of the liquid bridge (Vl) between two particles can be calculated according to Pietsch and 
Rumpf 14 with equation 3: 
     {   
         
             
  
          
 
   
        [                  (
 
 
   
 )  
  
 
 
                 ]} (3) 
In case of particle size polydispersity the proposed concept is valid, however, the values for packing 
efficiency and bridge volumes will not be the same.  
 
1.3 Aim 
The aim of this study was to investigate the appearance of liquid bridges of different configurations, 
which result in stepwise increase of the power consumption profile during a wet granulation. The power 
consumption profiles were analyzed as a function of liquid bridge volumes of specific configuration, 
bridge and particle configurations, and contact properties between the liquid and the pseudo-spherical 
particles as a model system. The calculated theoretical concentrations with changing bridge geometries 
were compared to the experimentally determined data.   
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2. Materials and Methods 
2.1 Materials 
Fujicalin® as a powder model for spherical particles was from Fuji Chemical Industry, Japan. Kollidon® 25 
(BASF, Germany) was used together with demineralized water as a binder. Isopropyl myristate was used 
as a dispersant for the particle size measurement. To determine the contact angle with the help of 
Washburn method, n-Hexane (VWR International, Belgium) was used as a non-polar liquid with contact 
angle around 0°.  
 
2.2 Methods 
2.2.1 Characterization of Fujicalin 
Fujicalin is a granulated form of calcium phosphate dibasic anhydrous with spherical and smooth 
particles of 120 µm in diameter. The granules can be used for direct compression due to exceptional flow 
and compression properties17. Shape and surface of Fujicalin were studied with a scanning electron 
microscope by using the FEI/Philips XL30 FEG apparatus (Philips, Netherlands). Before the 
measurement, the samples were sputtered with a 20 nm gold layer by a sputter coating machine (MED 
020, BalTec, Liechtenstein). 
Particle size distribution of Fujicalin was measured with a Mastersizer X long bed laser diffractometer 
(Malvern Instruments, UK). Fujicalin was dispersed in isopropyl myristate and analyzed with the help of 
the small volume sample presentation unit (Malvern Instruments, UK). The measurement was carried out 
in triplicate. The mean value of median particle diameter is shown with its standard deviation. 
Loss on drying (LOD) was measured gravimetrically for 10 minutes with an infrared lamp Mettler LP 16 
and a Mettler PE 360 balance (Mettler Instruments, Switzerland).  
 
2.2.2 Characterization of binder solution  
To measure the density (n=3) of the binder liquid, the Kollidon 25 solution was filled into a volumetric 
flask (V = 250 ml) and the weight was measured with a Mettler PB3002-L balance (Mettler Toledo, 
Switzerland). Density was calculated according to equation 4: 
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 (4) 
where  is the density (g/ml), m is the mass (g), and V is the volume (ml). 
Viscosity of the binder solution was measured with a capillary viscometer (SI Analytics GmbH, Germany) 
according to the Ph.Eur. capillary viscometer method 18. The measurements for all binder concentrations 
were performed in triplicate. Viscosity was calculated according to equation 5: 
        (5) 
where µ is the dynamic viscosity (mPas), k is the constant of the apparatus (mm2/s2),  is the density of 
the binder solution (g/ml), and t is the flow time of the sample (s).    
Surface tension, contact angle, and speed of liquid uptake (n=3) were measured with a tensiometer 
K100MK2 (Krüss GmbH, Germany). Surface tension was detected according to du Nouy ring method. 
Contact angle and speed of water uptake were measured with the sorption method with the help of 
laboratory desktop software 3.1 (Krüss GmbH, Germany). 
 
2.2.3 High shear granulation of Fujicalin particles 
One liter of Fujicalin was put into the Oystar Micromix high shear mixer (Hüttlin GmbH, Germany). The 
mass of particles was calculated according to equation 6: 
            (6) 
where m is the total mass of Fujicalin (g), tapped is the tapped density (g/ml) measured according to 
Ph.Eur. 18, and V is the total volume of the sample in the vessel (ml). Impeller speed was set to 150 rpm 
and chopper speed was adjusted to 1500 rpm. Kollidon 25 was added as a 10%, 15%, and 20% (w/w) 
solution at a spray rate of 11.3  0.3 g/min (Vario-Pumpsystem, Ismatec SA, Switzerland). Impeller 
speed, chopper speed, torque, and temperature were registered with the data recording software 
version 1.10 (Hüttlin GmbH, Germany) during the granulation process. Granulation was stopped after 
formation of big lumps (> 10 mm in diameter).  
 
2.2.4 Calculation of required binder amount for granulation 
Liquid bridge volume 
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The volume of the liquid bridge between two granulated particles was calculated according to equation 1, 
2, and 3 (chapter 1.2 “Theoretical considerations”). The volume in equation 3 is strongly dependent of 
the contact angle () and the half-filling angle (). In case of contact angle we experimentally measured 
this parameter; however, for the half-filling angle the experimental observations were limited. In the work 
of Gröger 16 the half-filling angle was simulated (with respect to the minimum separating distance h) 
versus dimensionless tensile force of the liquid and expresses a maximum in the range of 15 degrees 16. 
We used this value (i = 15°) as a constant to calculate the volume of the single liquid bridge throughout 
this study.  
Parameter si from equation 1 was set to 0, meaning that the particles touch each other. We assumed 
that the particles are ideal spheres with shape factor of 1 and that no liquid sorption into the particles 
takes place. Furthermore, we assumed that the surface tension and contact angle of the granulation 
liquid are constant over the change of process parameters, i.e. temperature; and are invariant to 
concentration change due to evaporation. We also assumed that i is constant for all three 
concentrations of binder liquid. 
Calculation of wetting ratio (W)  
Scheel et al. have shown that one particle can build maximum 6 bridges before the liquid starts to 
coalescence and a trimer structure is obtained 5. The amount of liquid needed to build a network through 
the granulation vessel where every particle builds 6 liquid bridges is shown in equations 7-12. In a first 
step the volume of one particle was calculated according to equation 7: 
          
 
 
    (7) 
where VParticle is the volume of one particle (mm
3) and r is the radius of a particle (mm). 
With the help of equation 8 we determined the volume of solids in the high shear mixer: 
              (8) 
where VSolid is the volume of solids in the high shear mixer (mm
3), V is the volume of the particles from 
equation 6 (V=1106 mm3), and 0.64 is the value for Kepler conjecture for randomly packed spheres 12. 
The number of particles (NParticles) in the high shear mixer was calculated with equation 9: 
                            (9) 
The wetting ratio (W), defined as liquid volume divided by the total sample volume was calculated with 
equation 10: 
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                      (10) 
where Vl is the volume of one liquid bridge (ml) between two particles (equation 3), number 6 is related 
to the maximum number of bridges one particle can build 5, and V is the total volume of the sample in the 
vessel from equation 6 (V=1000ml).  
 
2.2.5 Evaluation of torque profiles 
To evaluate the torque profiles and to determine the first transition from phase I to phase II a user-
defined double linear curve fit was used. Equation 11 shows the two linear equations from the user-
defined double linear curve fit. The equations were fitted with OriginPro version 8.5 (OriginLab 
Corporation, USA). Figure 3 shows a schematic representation of the user-defined double linear curve 
fit. 
                           
                            (11) 
where T is the torque (Nm), t is the time (min), and k is the slope of the linear curve (Nm/min). The point 
where Ta=Tb is the intersection point of these two linear curves and hence the point of interest. The 
intersection point (t) was calculated according to equation 12. 
  
     
     
 (12) 
 
 
 
 
 
Figure 3: Schematic presentation of a 
user-defined double linear curve fit. 
The intersection point (t) indicates the 
start of the granulation process and 
hence the transition from phase I to 
phase II.  
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2.2.6 Particle size distribution analysis 
To determine the particle size distribution during granulation, we stopped the granulation processes at 
certain time points (5 to 25 minutes, in 5 minutes intervals). The granules were dried in a Heraeus 
UT6200 oven (Heraeus, Germany) to a residual moisture content of 2.0 ± 0.6 %. We used a vibrating 
sieve tower (Vibro Retsch, Switzerland) to perform the particle size distribution analysis. The sieving 
tower was shaken for 10 minutes at a shaking displacement of 1.5 mm. We used steel wire screens 
(Vibro Retsch, Germany) with mesh sizes 90 µm, 125 µm, 180 µm, 250 µm, 355 µm, 500 µm, 710 µm, 
1 mm, 1.4 mm, 2 mm, 2.8 mm, and 4 mm. The amount of powder remained on each sieve was 
weighted.  
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3. Results and Discussion 
3.1 Characterization of Fujicalin 
Figure 4 shows two scanning electron microscope (SEM) images of Fujicalin at different magnifications. 
The particles were spherical with a narrow particle size distribution. Fujicalin had a median particle size 
of 117.37 ± 0.07 µm.  
During LOD measurement there was no change in weight (LOD=0%). 
 
 
Figure 4: Electron micrographs of Fujicalin at two different magnifications. Left image: scale bar = 300 µm. Right image: 
scale bar = 50 µm. 
 
3.2 Characterization of binder solution 
Table 1 shows that the three different concentrations of Kollidon 25 binder solution were different in their 
physical properties. The more concentrated the solution was, the higher was the density and viscosity. 
With the speed of liquid uptake it was directly the opposite; the higher concentrated the binder solution 
was, the slower was the liquid uptake. The 15% (w/w) binder solution showed the highest value for 
surface tension and for contact angle. The lowest value for the contact angle was measured for the 20% 
(w/w) binder solution and the 10% (w/w) binder solution showed the lowest value for the surface tension. 
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Table 1: Physical properties of the binder solutions. Values are means ± SD of n=3 experiments. 
Property 10% (w/w) Kollidon 25 15% (w/w) Kollidon 25 20% (w/w) Kollidon 25 
Density (g/ml) 1.02  0.00 1.03  0.00 1.04  0.00 
Viscosity (mPas) 5.1  0.0 11.2  0.0 22.2  0.1 
Surface tension (mN/m) 55.79  1.12 64.72  0.07 60.99  0.13  
Contact angle (°) 54.11  1.00 55.66  0.95 49.91  1.73 
Speed of liquid uptake (mg/s) 281.3  3.4 202.6 ± 2.5 150.6 ± 2.7 
 
 
3.3 High shear granulation of Fujicalin 
Figure 5 shows four different morphologies of liquid bridges as described by Scheel et al. 5. In our study 
we calculated the volume of a liquid bridge between two particles with the equation of Pietsch and 
Rumpf 14. This equation is based on the assumption that the liquid bridge has the shape of a capillary 
bridge (cb), as shown in Figure 5a. Scheel et al. have published the volumes (voxels) of the different 
morphologies of the liquid bridges. With respect to their results, a trimer (tr) contains 4 times the volume 
of a capillary bridge (cb), a pentamer (pt) contains 8 times the volume of a capillary bridge, and the 
tetrahedra (th) contains 12 times the volume of a capillary bridge 5.  
 
Figure 5: Schematic illustration of liquid morphologies. Arrangement of particles are characterized by 1, 3, 5, and 6 contact 
points between the particles 
5 
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Based on these findings, we calculated the wetting ratios (W) for the different liquid morphologies as 
shown in Table 2. Therefore, equation 10 was slightly modified by multiplying the liquid volume (Vl) with 
the factor mentioned above (e.g. factor 4 for a trimer structure). For a case of 6 liquid bridges per particle 
the value for Wcb yielded between 2.08% and 2.46% for the different binder concentrations, which is in a 
good agreement with the results of Scheel et al., i.e. 2.5% 5. Figure 6 shows the torque profiles for the 
Fujicalin granulation with different binder concentrations. The data points for Wcb ~ 2.3% are located at 
the very beginning of the granulation process.  
For Wtr we obtained between 8.31% and 9.85%, depending on the concentration of the binder solution. 
We observed that Wtr was the granulation start-point, i.e. the point when the granular formulation starts, 
meaning that the torque was increasing for the first time (Figure 6) at this data point. Although the initial 
increase of the torque at this moment was faint, we assumed that this event will be significantly amplified 
by increased scale of production. The results from the fitting of the double linear curve fit revealed similar 
results; the intersection point was found at 12% ± 0.1%. Scheel et al. 5 reported that about 90% of the 
liquid belongs to one cluster at W = 9%. Based on our results we assumed that the formation of capillary 
bridges within the powder bed could not be detected by the torque sensor in the high-shear mixer. At 
W ~ 10%, the liquid bridges transformed from the capillary bridge structure to trimer structures. The 
network of the trimers seemed to be more stable and, therefore, resulted in an increase of torque.  
For Wpt we received values between 16.61% and 19.70% for the different binder solutions. At this point, 
phase II ended up and phase III was reached.  
Wth was found to be between 24.92% and 29.55%, depending on the used binder liquid. In contrast to 
the trimer and pentamer structure, the tetrahedral structure can be considered as most efficient packing 
and is normally more stable. This was the reason, why the tetrahedral structure was more robust and the 
torque increased significantly because a lot of force was needed to destroy a network of dense packed 
tetrahedras.  
 
Table 2: Wetting ratios (W) of different liquid morphologies for the different binder concentrations. Values are means ± 
SD of n=3 experiments. 
Liquid morphologies 10% (w/w) Kollidon 25 15% (w/w) Kollidon 25 20% (w/w) Kollidon 25 
Wcb with 1 Vl (%) 2.33  0.07 2.46  0.09 2.08  0.08 
Wtr with 4 Vl (%) 9.33  0.30 9.85  0.37 8.31  0.34 
Wpt with 8 Vl (%) 18.65  0.59 19.70  0.73 16.61  0.67  
Wth with 12 Vl (%) 27.98  0.89 29.55  1.10 24.92  1.01 
 
The particle size distribution analysis supported our findings. We observed a bimodal particle size 
distribution with maxima at 180 µm and 1000 µm. Figure 6a shows that during the high-shear granulation 
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of Fujicalin with the 10% Kollidon 25 binder 
solution, the 1000 µm sieve fraction started to 
increase shortly before Wpt was reached and at 
the same time the 180 µm sieve fraction 
decreased significantly, indicating the formation of 
agglomerates. Based on these findings we 
propose the granulation end-point to be between 
Wpt and Wth.  
In general we observed that the higher the 
viscosity of the binder solution, the later was the 
onset of the different phases in the power 
consumption profile. Based on the results shown 
in Table 1, the speed of liquid uptake into the 
powder bed was significantly slower for the higher 
concentrated binder solution compared to the less 
viscous binder liquid. We concluded, that highly 
viscous binder liquids have to be sprayed slower 
to distribute homogenously within the granulation 
vessel than less concentrated binder liquids. In 
case there is not sufficient time given to the 
viscous liquid to thoroughly distribute within the 
granulation vessel, the geometrical transitions 
from cb to th will happen all at once. The result will 
be a power consumption profile with one peak, 
which will indicate the point of no return.  
 
 
 
 
Figure 6: Theoretical predictions and experimental torque profiles. Torque profiles and particle size distribution during 
Fujicalin high-shear granulation with 10% (w/w), 15% (w/w), and 20% (w/w) Kollidon 25 binder solution (top to bottom). The 
white curve is a smoothed version of the measured torque curve. The grey boxes with the arrows indicate the different phases 
during the granulation and were obtained by calculation.  
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3.4 Applicability of proposed method to other particles geometry 
Application of the proposed method to formulations with more complex particle geometries is 
theoretically possible; however, it has to be adapted. We consider several typical cases which could be 
found also co-existent with each other: spherical particles with different diameters, porous particles, non-
spherical particles, and particles which are changing their sizes during granulation. 
As a separate scenario the changes of the contact angle could be considered; moreover, it is one of the 
likeliest phenomena which co-exist together with other effects. The consequence of all of the above-
mentioned effects is the change in particle-particle bridge geometries and liquid bridge volumes, 
consequently. In the case when bridge volume for a prevalent transitional geometry (e.g., pentamer or 
tetrahedron) changes, the multiplication factor will become different to the values used in this study. 
Indeed, these multiplication factors can be determined experimentally with the same method used by 
Scheel et al.5. 
With respect to theoretical adaptations of the proposed model to the case of different particle radii, the 
equation of a liquid bridge volume can be adapted. In such case, the equations 1 and 2 will account for 
different particle radii and the cubed radius in equation 3 can be averaged. Despite a relative simplicity of 
such corrective approach it has an important limitation. In case of different interacting particle radii, the 
more complex agglomerates such as trimers or pentamers, will have different geometries; thus, result in 
different or slightly different bridge volumes and, consequently, into different multiplication factors. 
In case of particles with high intraparticle porosity, such as FCC 19,20, the granulation liquid will be first 
absorbed to saturation before any agglomeration effects will take place. However, for such cases the 
contact angle between particles will be different to the contact angle of liquid to a solid material. It has to 
be kept in mind that particles with closed or very narrow pores (10-100nm) will not absorb granulation 
liquid significantly; thus, the porosity of such particles can be neglected. 
The complexity of the task rises for heterogeneous geometries of the granulated powder beds. In case of 
spherical interacting particles the simple liquid particles have rotational symmetry; for more complex or 
mixed geometries such symmetry will not hold, making analytical solutions for bridge volume very 
difficult. In such a case, the numerical simulation of the liquid bridge geometry for static configurations is 
necessary. A simple and convincing approach is given in 21. 
The case of changing particle diameters during granulation liquid addition due to solubilizing of the solid 
material represents one of the most complex cases during wet granulation and can only be taken into an 
account in numeric simulation.  
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4. Conclusion 
Analysis of power consumption profiles during granulation suggests that formation of liquid bridges 
between particles is a sequential and ordered process. Spherical particles are aligned in specific 
geometrical arrangements at increasing liquid content. The higher the available amount of liquid, the 
more stable the configuration of the resulting agglomerate is, however, further increase in granulation 
liquid will result in an instability of current configuration and leads to further configuration change as long 
as inter-granular pores are not fully saturated with liquid. Transitions between states are induced by 
addition of liquid and assumed to affect all particles simultaneously throughout the powder bed (Figure 
7). These stepwise changes in geometrical arrangement of the spherical particles can be described by 
mathematical models. Thus, it is possible to predict the process end-point during granulation. We think 
that proposed theoretical considerations can be used in optimization of existing numerical models of 
agglomeration, which will find its use in the assessment and further development of the granulation 
methods and will lead to a development of more robust pharmaceutical formulations.  
 
 
 
 
 
 
 
Figure 7: New interpretation 
of power consumption 
profiles during wet 
granulation. The different 
stages during a granulation 
process are characterized by 
the formation of distinct 
geometries of particles and 
liquid bridges and are a 
function of the total amount of 
liquid present in the system.  
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ABSTRACT
Purpose To overcome the limitation of insufficient hardness
during the production of rapidly disintegrating orally dispersible
tablets (ODTs). Furthermore, we investigated the properties
and usefulness of functionalized calcium carbonate (FCC) as a
new pharmaceutical excipient for the production of ODTs.
Methods A highly sensitive tensiometer-based method was
developed to measure kinetics of weight loss during tablet
disintegration. With this method we were able to determine
the residence time of tablets placed on a basket immersed into
a test medium. The shapes of tensiometer plots allowed us to
categorize substances into four different types of disintegration.
Results At the same volume and hardness, the tablet formula-
tions with FCC showed a significantly higher porosity (over
60%) than all other formulations. Residence time depended
mainly on the tablet composition rather than on porosity. When
combined with disintegrants, FCC formulations exhibited favor-
able disintegration properties, comparable to those of the
marketed drug risperidone oro (disintegration time ca. 10 s).
Conclusions Oral dosage forms - based on the new pharma-
ceutical excipient FCC - can be designed to have a short disinte-
gration time combined with good mechanical strength. Due to
these properties, FCC can be used for the preparation of ODTs.
KEY WORDS disintegration . ODT . porosity . residence
time . tensiometer
INTRODUCTION
Orally dispersible/disintegrating tablets (ODTs) constitute a
solid, single-unit dosage form which instantaneously
disperses/dissolves in the saliva (1). ODTs can be prepared
by different techniques, such as freeze drying (2,3), mould-
ing (4), spray drying (5), and mass extrusion (6). Depending
on the technique, the final form dissolves very rapidly (5–
15 s), but may be associated with low mechanical strength,
high production costs, low drug content, or limited stability
(7). The easiest technique to prepare ODTs is by direct
compression. With conventional equipment, a limited num-
ber of process steps, and commonly available excipients,
ODTs containing large amount of active ingredients can
be produced at low costs. However, disintegration capacity
of ODTs produced by this technique is limited by the size
and hardness of the tablets (8,9). Increased compression
force applied during tableting leads to harder tablets thus
increasing disintegration time (10). Consequently, ODTs
with optimal disintegration properties are often small
and/or have a low hardness and higher friability (8).
In accordance with the European Pharmacopeia, ODTs
should disintegrate within 3 min when tested with the con-
ventional disintegration apparatus (11). The American Food
and Drug Administration (FDA) requires an in-vitro disinte-
gration time of approximately 30 s or less (12,13). The
disadvantage of the conventional disintegration apparatus
is poor discrimination among rapidly disintegrating tablets
(14). Furthermore, the volume of the test medium (900 ml) is
relatively large, compared with the volume of saliva in the
mouth cavity (less than 6 ml) (15). Several techniques have
been proposed to measure the disintegration time of ODTs
(14,16–23). For example, one research group used the force
measurement detection to analyze the forces developed
during the disintegration process due to water absorption
(24). In our current work, we adapted the standard liquid
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absorption measurement by means of a tensiometer (25) to
accurately determine tablet disintegration time and mimic
disintegration in the patient’s mouth cavity. This method
employs the microbalance of the tensiometer to detect ki-
netics of weight loss during tablet disintegration. In addition,
the proposed method provides quantitative information on
dispersion kinetics, i.e., speed; ability to readily disperse in
small volumes of liquid (e.g., teaspoon); and to detect for-
mation of big swollen lumps.
Disintegration time of an ODT depends on the porosity
of the tablet. The rate of water uptake increases with higher
porosity of the ODT. Thus, disintegration rate increases
because of faster wetting of the tablet (26). On the other
hand, higher porosity of the ODT affects the hardness of the
resulting tablets hence compromising further processing of
formulations. Consequently, an ideal ODT combines two
controversial properties, i.e., higher porosity and higher
hardness. An excipient with combined functionality (highly
porous and providing strong grip between particles) has
been identified in paper industry.
Ridgway et al. modified a natural ground calcium car-
bonate to enhance porosity up to 60% (v/v) and enlarge the
surface area. This functionalized calcium carbonate (FCC)
absorbs water at a faster rate and is able to absorb 10 times
more fluid than conventional calcium carbonate (27).
The manufacturing process of FCC shows some similar-
ities to the production of precipitated calcium carbonate, an
established pharmaceutical excipient. Both substances are
produced by decomposition, once in aqueous solution (pre-
cipitated calcium carbonate) and once under acidic condi-
tions (FCC). The different conditions and different
concentrations lead to different shapes and different particle
size distributions of the particles (28,29).
The aim of the current work was to investigate the
properties and usefulness of FCC as a new pharmaceutical
excipient in the production of ODTs. Performance of FCC
was compared to that of other commonly used excipients
such as microcrystalline cellulose (MCC 102 and MCC
burst), and FlowLac (fillers) and AcDiSol, VivaStar, and
Kollidon CL as disintegrants.
MATERIALS AND METHODS
Materials
FCC (VP-220976 S02, Omya, Switzerland), directly com-
pressible calcium carbonate (Barcroft™ CS90, SPI Pharma,
Germany), calcium carbonate (PharMagnesia CC Type
Natur 120, Lehmann & Voss & Co., Germany), microcrystal-
line cellulose (MCC SANAQ® 102, Pharmatrans Sanaq AG,
Switzerland), and lactose monohydrate (FlowLac® 100,
Meggle, Germany) were used as fillers. As disintegrating
agents, modified cellulose gum (Ac-Di-Sol®, FMC, USA),
insoluble, cross-linked polyvinylpyrrolidone (Kollidon® CL,
BASF, Germany) and sodium starch glycolate (Vivastar®,
JRS, Germany) were selected. A special kind of microcrystal-
line cellulose (MCC SANAQ® burst, Pharmatrans Sanaq
AG, Switzerland) was used both as filler and disintegrant.
The market ODT formulation, Risperidone-Mepha® 0.5
oro tablets, was used as a reference of a market.
Isopropyl myristate (Hänseler AG, Switzerland) was chosen
as a dispersant for particle size distribution measurements.
Methods
Characterization of FCC
The true density of FCC was determined by helium
pycnometry (Micromeritics AccuPyc 1,330, USA).
Scanning electron microscopy (SEM) images were
obtained using the FEI/Philips XL30 FEG apparatus
(Philips, Netherlands). Before measurements, the samples
were sputtered with a 40 nm gold layer by a sputter coating
machine (MED 020, BalTec, Liechtenstein).
Pore size distribution of FCC was determined with a
mercury porosimeter (AutoPore IV 9,500, Micromeritics
Instrument, USA). Low-pressure mercury intrusion ranged
from 3.59 kPa to 206.64 kPa. During high-pressure mercury
intrusion, the pressure ranged from 206.64 kPa to
206.78 MPa. For both high- and low-pressure intrusion,
equilibration time was 10 s.
To measure the specific surface area, Nova 2000e
(Quantachrome Instruments, USA) was used with the five-
point BET (Brunauer, Emmett, Teller) method. After
degassing the samples for 12 h at room temperature, the
samples were measured with nitrogen at constant temperature
(77.4 K). The measurement was performed in duplicate.
Particle size distribution was determined with the
Mastersizer X long bed (Malvern Instruments, UK). For
MCC 102, MCC burst, FlowLac, Barcroft, AcDiSol and
VivaStar, the dry powder feeder (Malvern) was used. These
measurements were performed in triplicate. Kollidon and
FCC were dispersed in isopropyl myristate and then ana-
lyzed (in duplicate) by using the small volume sample pre-
sentation unit (Malvern). The medians of the particle
diameter and their standard deviations are shown.
Tablet Preparation
All powders and formulations were mixed by using a tumbling
mixer (Turbula T2C, Switzerland) for 10 min at 32 rpm. The
tablets were compressed by a single punch press (Korsch EK0,
Berlin) with 11 mm round flat tooling. The punch gap was
adjusted to compact 500 mg of FCC powder into a tablet with
a hardness of 100 N. The resulting tablet had a height of
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5.30 mm. This setting for the punch gap was kept constant for
all other mixtures. The target hardness of 100 N was obtained
by changing the mass of the compacts. The powder was
introduced manually into the die. After compacting, the tab-
lets were stored in closed glass bottles in the room at 24±2°C
and at 40±5% relative humidity (measured values) for 30 days
to allow enough time for expansion.
We did not use any lubricant in order to avoid potential
influence of the lubricant distribution on the properties of
FCC in combination with a disintegrant. Due to manual
tableting, the speed of compaction was slower than with an
automated process, i.e. using hopper. The lower compres-
sion speed caused less friction; hence the tablets were not
damaged during ejection.
We could obtain the same tablet hardness with 0.5%
magnesium stearate. In order to exclude potential influence
of lubricants, we compressed 300 mg S02 powder at 4 kN.
For the tablets without magnesium stearate, we obtained a
hardness of 124±8 N, whereas the tablets with magnesium
stearate showed a hardness of 126±5 N.
The concentration of the disintegrant was kept constant
and comprises of 3% w/w in accordance to general recom-
mendations (30). Our focus was set on the comparison of
different filler excipients (e.g. FCC) on the disintegration
behavior in presence of different disintegrants. In addition,
our earlier experience in application of the percolation
theory to the tablet disintegration and water uptake has
revealed that the percolation threshold is located at 3%v/v
for AcDiSol (31). This value could be corroborated by
computer-based simulations of the percolation thresholds
carried out by Garboczi et al. (32). In accordance with these
results the optimal theoretical value lays in the area of 3%
v/v for elongated particles with aspect ratio approx. 20.
Tablet Characterization
To determine the mean tablet weight, tablets (n=13) were
weighted on an electronic balance (Mettler Toledo, type
XS204 DeltaRange, Switzerland). Tablet diameter (n=13)
was measured with a micrometer screw (Mitutoyo Model
CD-15CPX, Japan), and tablet thickness (n=13) was deter-
mined with a dial indicator (Compac type 532G,
Switzerland). Friability was measured by an ERWEKA
(type TA200, Germany). The hardness of the tablets (n=3)
was checked with a hardness tester (Tablet tester 8 M,
Switzerland). To determine the true densities, a helium
pycnometer was used (Micromeritics AccuPyc 1,330,
USA). Porosity ε (%) of the tablets was calculated with the
Eq. 1, as follows:
" ¼ 1
m
ρ
p  r2  h
 
 100 ð1Þ
where m is the tablet weight (g), ρ the true density of the
powder mixture (g/cm3), r the radius of the tablet (cm), and
h the height of the tablet (cm).
Method for Characterization of Disintegration and Dispersion
Kinetics
To characterize disintegration and dispersion kinetics of the
tablets (n=3, for FCCwithout disintegrants n=2) a tensiometer
(Krüss Processor Tensiometer K100MK2, Germany) was
used. The experimental setup was composed of a special
metal-wire basket (Fig. 1a) which was attached to the micro-
balance of the tensiometer with four nickel wires. For the
measurement of small tablets (such as risperidone oro tablets),
the mesh size was reduced by a nickel wire to a size of 4 mm×
4.5 mm. As shown in Fig. 1b, the basket was immersed to a
defined depth (12 mm) into a beaker. The beaker was filled up
to the edge with distilled water. The beaker was heated (37°C
±1°C) by the surrounding thermostatic water bath.
Weight loss versus time was recorded by the tensiometer
software. Figure 1c shows a schematic representation of this
plot. The tablet was placed manually on the basket immersed
in the water. With the aid of the tensiometer software, the
mass was plotted against the time. The time point at which the
tablet reached the basket and disintegration induced by water
absorption started was indicated as t0. At this stage, the weight
was increased due to water uptake. This was reflected as
weight increase on the profiles. The weight decrease was
explained as tablet disintegration upon water uptake. The
end of tablet disintegration was indicated by the leveling off
of the profile. This event was referenced as t1. The difference
between t1 and t0 (t1-t0) was the tablet residence time on the
basket. Residence time is a measure of disintegration time and
is a good indicator of the time needed to disperse the tablet in
the mouth cavity or on a spoon. To determine t0 and t1, the
two linear equations were fitted with OriginPro version 8.5
(OriginLab Corporation, USA). A user-defined double linear
curve fit was programmed with Eq. 2.
mabsorption ¼ m0 þ k0  t t < tc
melimination ¼ m0 þ k0  tc þ k1 t tcð Þt  tc ð2Þ
where m is the weight (g) and t is the time (s).
If ma and me are set equal to 0 and Eq. 2 is solved for t, the
following equations are obtained:
t0 ¼ m0k0
t1 ¼ tc  m0þk0tck1
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To calculate the residence time, Eq. 3 was used.
Δt ¼ t1  t0 ¼ tc  m0þk0tck1 
m0
k0
ð3Þ
In addition to the residence time, the disintegration de-
gree was calculated with Eq. 4:
n ¼ 1 mfinal
mmax
 
 100 ð4Þ
where n is the disintegration degree (%) and m is the weight
(g). For mmax the weight at time point tc was used, and mfinal
is the weight at leveling off of the profile (Fig. 1c).
Kinetics of Water Absorption (Tensiometer)
Water absorption capacity of the tablets (n=3) for each lot was
measured with a tensiometer (Krüss Processor Tensiometer
K100MK2, Germany) in a water bath (37°C±1°C). The
tablet was placed in a glass tablet holder with a ceramic filter
bottom. With the help of the software, time was plotted
against mass gain. The slope of this function indicated the
speed of water absorption, and the saturation level
corresponded to the relative amount of absorbed water. To
calculate the slope, the values for the time points between 6
and 9 s were taken into account. OriginPro version 8.5
Fig. 1 (a) Schematic representation of the basket. (b) Schematic representation of the experimental setup for measuring the residence time. (c) Schematic
representation of the mass versus time plot from the tensiometer software.
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(OriginLab Corporation, USA) was used for curve fitting and
the evaluation of tensiometer plots.
RESULTS
Properties of Fillers (F) and Disintegrants (D)
Figure 2a-c shows SEM pictures of FCC at different mag-
nifications. The size of the FCC particles was around 7 μm.
The particles showed a multitude of thin lamellae that
formed a porous meshwork. Figure 2d illustrates the mer-
cury porosimetry plot of FCC.
Table I shows the true densities and medians of the
particle diameter of the used substances. With the BET
method a specific surface area of 62.14±0.19 m2/g was
measured for the FCC particles.
Evaluation of Tablet Properties
Table II lists the properties of the tablets. At the same volume
and hardness (100 N), the tablets with FCC and MCC 102
were the lightest (around 500 mg). By comparison, CS90
tablets were approx. 1.7 times heavier (approx. 840 mg) than
the tablets consisting of FCC and MCC 102. Friability was
1.0% to 1.7% for all tablets except the formulations with
MCC 102, where a friability of approx. 0.5% was reached.
Although volume and hardness of the tablets were kept con-
stant, porosity of the tablets varied strongly between the
different tablet formulations. Tablet formulations with FCC
had a porosity of over 60% whereas the MCC 102-based
tablets exhibited a porosity of only 40% at the same weight.
With porosities of about 25% and 35%, the tablets consisting
of FlowLac and MCC burst were less porous than MCC 102
tablets. Formulations with CS90 had a porosity of approx.
35% and weighed approx. 840 mg.
Calcium carbonate Natur 120 was not suitable for the
preparation of tablets with the desired properties. The target
hardness (100 N) was not reached due to capping of the tablets.
Table III shows the residence times and disintegration
degrees obtained after a double linear curve fit of tensiom-
eter weight versus time plots (Fig. 1).
In addition, Table III indicates the speed of water absorp-
tion and amount of absorbed water after 90 s. Some formu-
lations with FCC, MCC 102, and MCC burst reached a
water absorption speed of more than 50 mg/s. Only MCC
102 and MCC burst formulations absorbed water at a speed
of more than 100 mg/s. The formulations with MCC burst
showed the highest absolute amount of absorbed water.
As pointed out above, an ODT should disintegrate with-
in 3 min if tested with the standard disintegration test
according to the European Pharmacopeia (11). Figure 3
illustrates the influence of tablet composition on residence
time. The horizontal line indicates a residence time of
3 min. With the fillers FCC and FlowLac, three formula-
tions in each case had a residence time of less than 3 min. In
comparison with FlowLac, the FCC formulations had a sig-
nificantly shorter residence time. FCC formulations showed
Fig. 2 (a-c) SEM pictures
of FCC (magnifications: (a) x 300,
(b) x 3,000, and (c) x 10,000).
(d) Mercury porosimetry
plot of FCC.
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fast disintegration comparable to that of MCC burst and
MCC 102 formulations. It is important to note that FCC
formulations compared well with the reference tablets, risper-
idone oro. On the other hand, it has to be kept in mind that
FCC had to be used in combination with a disintegrant to
trigger the fast dispersion. For all tablets with a residence time
below 3 min, a disintegration degree between 85% and 100%
was calculated. Nevertheless, Table III shows that not all of
the tablet formulations had residence times below 3 min. We
marked the residence time values as ∞ if calculated residence
time (Δt) indicated that water absorption was not followed by
tablet disintegration.
DISCUSSION
Tensiometer Method
The present work describes a novel strategy for the design of
orally dispersible tablets (ODT). Functionalized calcium car-
bonate (FCC) was used as the main pharmaceutical excipient
for ODTs, which are characterized by a very short disintegra-
tion time (i.e. <10 s). This rapid process is a challenge, in that
conventional disintegration protocols according to the
European Pharmacopeia cannot be used. This standard meth-
od relies on a vertically moving sample holder. This leads to
forced disintegration of tablets due to mechanical stress. For
example, formulations containing spray dried calcium carbon-
ate (i.e. the Barcroft formulations), did not disintegrate in an
unstirred solution. Upon agitation only, tablet fragments are
dislocated from the tablet surface. FlowLac based formulations
Table I True Density and Median Particle Diameter of the Substances
(Where F Stands for Function as Filler and D Stands for Disintegrant)
Substance Function in a
formulation
True density
(g/cm3)
Median particle
diameter (μm)±SD
FCC F 2.7382 7.28±0.05
Barcroft CS90 F 2.5233 163.52±10.00
MCC 102 F 1.5583 120.65±1.31
FlowLac F 1.5412 150.37±2.19
MCC burst F+D 1.5337 64.04±0.14
AcDiSol D 1.5996 43.74±0.06
VivaStar D 1.4778 41.20±0.12
Kollidon CL D 1.2374 91.64±0.81
Table II Tablet Properties
Tablet formulation Diameter
(mm) (n=13)
Thickness
(mm) (n=13)
Weight (mg) ± SD
(n=13)
Hardness
(N) ± SD (n=3)
Friability (%)
(n=1)
Porosity (%)
FCC 11.02±0.01 5.30±0.02 499.4±2.9 117.3±15.0 1.06 64
FCC+3% AcDiSol® 11.03±0.01 5.41±0.01 498.9±1.9 99.7±9.6 1.32 64
FCC+3% Viva Star® 11.01±0.01 5.36±0.05 502.3±0.8 107.0±3.5 1.67 64
FCC+3% Kollidon® CL 11.02±0.01 5.14±0.01 499.2±1.0 116.7±19.2 1.18 62
FCC+3% MCC burst 11.03±0.01 5.20±0.09 500.8±1.6 111.7±21.1 1.10 63
Barcroft™ CS90 11.07±0.00 5.47±0.01 851.7±1.4 95.3±1.2 1.12 36
Barcroft™ CS90+3% AcDiSol® 11.08±0.00 5.58±0.01 845.3±1.2 88.3±2.5 1.25 37
Barcroft™ CS90+3% Viva Star® 11.08±0.01 5.50±0.01 845.9±1.3 94.7±2.9 1.14 36
Barcroft™ CS90+3% Kollidon® CL 11.07±0.00 5.51±0.01 833.0±1.5 98.3±3.8 1.12 37
Barcroft™ CS90+3% MCC burst 11.06±0.00 5.49±0.01 836.9±1.1 95.7±0.6 1.20 36
FlowLac® 11.05±0.01 5.32±0.01 594.4±2.7 88.3±3.2 1.46 24
FlowLac®+3% AcDiSol® 11.06±0.01 5.33±0.01 593.3±1.3 86.3±2.1 1.28 25
FlowLac®+3% Viva Star® 11.06±0.00 5.34±0.01 598.7±0.8 88.3±5.0 1.40 24
FlowLac®+3% Kollidon® CL 11.06±0.00 5.35±0.02 595.0±1.2 89.3±3.2 1.50 24
FlowLac®+3% MCC burst 11.06±0.01 5.34±0.01 605.4±2.7 97.3±7.8 1.16 23
MCC 102 11.06±0.01 5.53±0.02 489.0±3.6 93.0±7.5 0.54 41
MCC 102+3% AcDiSol® 11.06±0.01 5.55±0.02 494.0±2.8 93.3±2.1 0.38 41
MCC 102+3% Viva Star® 11.07±0.01 5.54±0.03 498.3±2.3 96.0±1.0 0.51 40
MCC 102+3% Kollidon® CL 11.06±0.01 5.55±0.02 487.9±1.8 98.3±3.5 0.48 41
MCC 102+3% MCC burst 11.07±0.01 5.54±0.02 493.6±2.0 92.3±3.5 0.59 41
MCC burst 11.10±0.01 5.83±0.03 566.6±2.9 88.7±3.8 1.52 34
MCC burst+3% AcDiSol® 11.09±0.01 5.75±0.03 563.3±1.9 94.0±3.5 1.38 34
MCC burst+3% Viva Star® 11.08±0.01 5.84±0.02 573.8±1.8 90.0±0.0 1.64 33
MCC burst+3% Kollidon® CL 11.10±0.01 5.82±0.02 566.5±1.3 86.7±3.8 1.53 34
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have a similar behavior in that tablets are fractured by agita-
tion. However, this “accelerated” or “forced” disintegration
does not reflect the intended use of our ODT formulations.
Here, disintegration in unstirred liquid (i.e. in a spoon prior to
oral administration) is needed. We were therefore forced to
develop our own disintegration method. As expected, the dis-
integration time for most formulations was shorter for the
standard method as compared to our tensiometer method. In
particular, MCC based formulations swell only and do not
disintegrate if not agitated. An additional advantage of our
tensiometer based method is its ability to monitor rapid disin-
tegration processes with very high precision. In addition, a
slight modification of the experimental setup allows for quan-
tification of the absorbed amount of water. Thereby, the type,
volume, and temperature of fluid can be varied.
FCC as a New Pharmaceutical Excipient
for the Production of ODTs
Comparison between FCC and Barcroft showed considerable
differences in the porosity. FCC-containing formulations (with
disintegrants) showed the best results. Formulations combining
FCC with a disintegrant disintegrated/dispersed within a few
seconds. Thereby, the mode of action of the different
disintegrants had no significant influence on the residence
time. Furthermore, all formulations of FCC combined with
disintegrants belonged to the disintegration type I and showed
a disintegration degree of 100%. We successfully produced
tablets with marked porosity and high hardness.
Properties of FCC
Several studies have demonstrated that porosity has a sur-
prisingly low impact on the disintegration behavior of FCC.
Figure 4 correlates speed of water absorption and the
absorbed amount of water after 90 s for FCC combined
with different excipients. Speed of water absorption and
absorbed amount of water after 90 s for each formulation
were influenced by the disintegrants only.
For FCC as well as all other excipients, no correlation
could be shown between the tablet weight and disintegration
degree (Table II and III). Disintegration degree was only
dependent on the composition of the tablet formulations.
Residence time also depended on the tablet composition and
Table III Calculated Parameters for Residence Time, Disintegration Degree, and Kinetic of Water Absorption
Tablet formulation Residence
time (s)
Disintegration
degree (%)
Disintegration
type (I-IV)
Amount of absorbed
water after 90 s (g)
Speed of water
absorption (mg/s)
FCC ∞ 0 II 0.189±0.011 4.5±0.33
FCC+3% AcDiSol® 8.92 100 I 1.232±0.018 80.4±2.69
FCC+3% Viva Star® 11.94 100 I 1.599±0.055 86.8±3.95
FCC+3% Kollidon® CL 9.53 100 I 0.816±0.007 37.9±0.92
FCC+3% MCC burst 4858.26 2 II 0.229±0.008 4.9±0.54
Barcroft™ CS90 ∞ 0 II 0.115±0.013 0.7±0.09
Barcroft™ CS90+3% AcDiSol® 7703.4 4.7 II 0.080±0.033 1.9±0.05
Barcroft™ CS90+3% Viva Star® 197.68 100 III 0.263±0.015 5.9±0.29
Barcroft™ CS90+3% Kollidon® CL ∞ 0 II 0.074±0.037 1.6±0.24
Barcroft™ CS90+3% MCC burst ∞ 0 II 0.113±0.021 1.1±0.19
FlowLac® 61.92 100 III 0.311±0.044 5.4±2.06
FlowLac®+3% AcDiSol® 127.85 100 III 0.322±0.016 5.5±0.29
FlowLac®+3% Viva Star® 194.2 100 III 0.667±0.026 16.2±1.64
FlowLac®+3% Kollidon® CL 65.09 100 III 0.375±0.017 9.8±0.33
FlowLac®+3% MCC burst 64.57 85 III 0.344±0.045 9.1±0.95
MCC 102 ∞ 0 II 0.807±0.040 79.2±17.95
MCC 102+3% AcDiSol® 1681.78 47.2 IV 1.306±0.017 82.3±13.61
MCC 102+3% Viva Star® 9.65 99.1 I 1.840±0.050 152.9±27.09
MCC 102+3% Kollidon® CL ∞ 0 IV 0.877±0.016 70.1±15.83
MCC 102+3% MCC burst ∞ 0 II 0.847±0.044 71.0±12.97
MCC burst ∞ 0 IV 1.741±0.059 96.6±5.63
MCC burst+3% AcDiSol® 5.92 96.3 I 1.864±0.052 70.9±3.22
MCC burst+3% Viva Star® 10.4 100 I 2.347±0.034 98.1±4.64
MCC burst+3% Kollidon® CL ∞ 0 IV 1.826±0.054 104.9±13.24
Risperidone oro 17.26 100 I - -
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was not affected by the porosity or weight of the tablets. This
latter finding was surprising since it has been suggested re-
cently that porosity might be an important property of ODTs
(26). Again, the combination of filler and disintegrants seems
to be the decisive factor, which appears to be a unique
property of FCC. All other excipients studied did not show
such a linear correlation (data not shown). This result suggests
that the speed of water absorption is modulated by
disintegrants. In the case of FCC, water absorption is a pre-
requisite for disintegration since pure FCC neither absorbs
water nor disintegrates. Thus, the choice of a specific
disintegrant is not a critical factor.
From the percolation theory point of view, disintegration
occurs above critical concentrations (threshold) of the
disintegrant (33). In our study, all formulations had
disintegrant concentrations close to the theoretically predicted
critical value, i.e., approx. 3% (v/v). At these concentrations,
the rate of disintegration is mostly governed by the type of
disintegrant rather than by tablet porosity (33).
Definition of Disintegration Patterns
We were able to distinguish four typical disintegration pat-
terns (Table III and Fig. 5).
First, excipients such as FCC and the commercial refer-
ence, ODT formulation of risperidone oro, showed a classical
disintegration pattern. Initially, absorption of water is faster
than disintegration (increase in mass). After reaching a peak,
the tablet continuously dispersed (decrease in mass) into very
small particles. This desirable property has been termed dis-
integration type I. In sharp contrast, non-modified calcium
carbonate particles (Barcroft) did not disintegrate. This profile
was characterized by fast initial water absorption only. After
saturating the pores with water, the speed of the water ab-
sorption declined continuously. Some formulations reached a
plateau, whereas other formulations were still able to absorb
more water, forming a large swollen lump. This profile was
defined as disintegration type II. FlowLac was a typical rep-
resentative of disintegration type III, which was characterized
by nonuniformity in the disintegration phase caused by larger
fragments falling off the tablet and then through the mesh.
These parts needed some more time on the bottom of the
beaker to disperse completely. We could not establish whether
the fragments that had come loose were still dry on the inside.
Finally, cellulose-based excipients (i.e., MCC 102 and MCC
burst) combined properties of type I and type II disintegration
patterns: initial phase of swelling followed by partial disinte-
gration. This profile termed disintegration type IV.
Owing to the new and very sensitive tensiometer method,
ODTs could be categorized based on their disintegration
profiles (Table III).
Fig. 3 Influence of tablet
composition on
residence time.
Fig. 4 Correlation plot between speed of water absorption and absorbed
amount of water after 90 s.
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Quantitative Model for Residence Time
Disintegration profiles can be evaluated using a user-defined
double linear curve fit model. In the majority of cases, the
values of residence time determined from the tensiometer plot
(Fig. 5) agreed well with the calculated values in Table III.
Quantitative evaluation for profiles of type III was difficult
due to the larger parts of the tablets that had fallen through
the basketmesh (i.e., without dispersing/disintegrating), hence
shortening the residence time. Another limitation of themodel
was the discrepancy between measured and calculated values
for residence time for a few formulations that showed an
exponential function within the tensiometer plot.
It should be emphasized, that disintegration of tablets is a
complex process. Figure 1c shows a disintegration profile,
which is characterized by a series of sequential events. In a
first step, the tablet was wetted by the medium, followed by
medium absorbance and disintegration. Thus, the tablet
mass increased until equilibrium was reached between liq-
uid sorption and mass decrease due to disintegration.
Afterwards, the disintegration predominated the water sorp-
tion resulting in a net loss of mass.
In many instances (Fig. 5), the disintegration pattern is
more complex. For example, some materials first soak up
liquid very fast and subsequently start to disintegrate by
heterogeneous fractionation. Other materials like FCC soak
up water at moderate speeds, leading to continuous disinte-
gration and loss of mass.
Several mathematical models can be used to describe
these processes. For example, the concurrent effects could
be modeled by the system of two differential equations (here
combined into one equation):
d
dt
mðtÞ ¼ M0ekat  kemðtÞ;
Fig. 5 Tensiometer plots for 4 types of disintegration kinetics (mass versus time). Re-normalized curve (with mass maximum at 0.0223 g).
Fig. 6 Correlation plot between the amount of absorbed water after 90 s
and residence time for the different disintegration types.
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where m(t) is mass detected by tensiometer, t is the time, M0
is compact mass in the test media, and Ka and Ke are the
absorption and disintegration speed constants, respectively.
However, the obtained model – although it’s good illustra-
tive properties – does not produce fits of experimental data of
sufficient quality. The reason for this is that the disintegration
behavior is not monotonous on the whole disintegration time-
line. For example, the lactose-based formulations were
disintegrating by losing larger pieces of mass, hence producing
“step-wise” profiles. Such profiles produce poor fitting of the
exponential equations, hence we had to discard this approach.
In order to take into account such inhomogeneous effects the
differential model should be modified or substituted by
another, – perhaps, discrete – model.
An alternative polynomial fit of the curves was not favor-
able due to a potential risk of over fitting.
For this publication we used a simplified linear model,
which gave best results in all encountered situations.
Utilizing this approach, we can determine the residence
time of the pharmaceutical compact on the tensiometer
sample basket.
Optimal Type I Disintegration of FCC
Figure 6 shows a correlation plot between the amount of
absorbed water after 90 s and residence time for the differ-
ent disintegration types. Due to very long or even unlimited
residence time, disintegration type II and type IV were of no
interest for the production of ODTs. Although the majority
of formulations of disintegration type III had a residence
time below 3 min, type III was limited by nonuniform
disintegration. Disintegration type I showed the shortest
residence time and was therefore the most appropriate for
producing ODTs. Within type I, the formulations are better
the shorter the residence time and the lower the amount of
absorbed water after 90 s. The absorbed amount of water is
important with respect to patient compliance in the clinical
setting. We assume that a pleasant mouth feel can be
achieved with tablets dispersing in small amounts of saliva.
If more saliva is absorbed by the ODT, patient’s mouth feels
dry, and swallowing of the tablet becomes difficult.
Therefore, we conclude that FCC-based formulations were
the best. When combined with disintegrants, FCC formula-
tions showed a disintegration pattern of type I, comparable
to that of the market reference drug, risperidone oro.
CONCLUSION
ODTs are designed to disperse within seconds. The prereq-
uisite for reliable classification and quantification of disinte-
gration properties of ODTs is the availability of a fast
analytical method.
In order to compare ODT tablet formulations containing
FCC, we introduced a new method to characterize the
disintegration/dispersion kinetics and swelling properties of
ODTs. With this method we were able to detect the exact
amount of absorbed water after 90 s, speed of water absorp-
tion, and residence time of a tablet placed on a basket
immersed into water with a single instrument.
We conclude that FCC has the required properties to
produce ODTs, such as a fast disintegration, and sufficient
mechanical strength. To fulfill the requirements for a short
disintegration time, the FCC formulations have to contain
superdisintegrants. The FCC formulations absorbed
smallest amount of water, which would enhance patient
compliance in the clinical setting.
FCC is a new pharmaceutical excipient, which can be
used to assist in the preparation of orally dispersible tablets.
ODTs prepared using FCC as main excipient are charac-
terized by a short disintegration time and high mechanical
strength. Thus, drug delivery to the buccal cavity or upper
esophageal regions can be achieved. The oral sensation after
ingesting FCC particles is expected to be favorable since
particles with a particle size below 15 μm are not felt in the
mouth (34). Further experiments are required to study the
friability and flowability of FCC particles being a prerequi-
site for large scale production.
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Chapter 4
Discussion
FCC is a co-processed excipient, invented by the company OMYA R© Development AG in Oftringen,
Switzerland. The excipient is produced by re-crystallization of inorganic mixed salts such as calcium
phosphate, incorporating the starting material calcium carbonate under controlled conditions to
form micro- to mesoporous particles [75]. Originally the particles were designed to be used in the
paper industry, more precisely in the field of inkjet printing technology. The unique structure of
FCC was successfully used to load water-based ink into the pores [76].
In the context of this thesis, FCC was used in the field of pharmaceutical technology for the first
time. Even though FCC and ground calcium carbonate have the same main constituent, they
revealed very different physical properties. The two main differences between FCC particles and
ground calcium carbonate are the high volume of intraparticle porosity of FCC and the significantly
higher specific surface area of FCC due to the lamellar structure of the FCC particles.
4.1 Lamellar structure as a key factor
The mechanical study of FCC showed that the special physical attributes of FCC particles result
in tablets with high tensile strength and high porosity at compressive pressures that are much
lower than those needed for other excipients. It was assumed that the lamellar structure of the
particles, and hence, the large specific surface area of FCC are the main reasons for these exceptional
properties. On closer inspection it was realized that the available specific surface area is governed
by the pore size distribution of intraparticle pores. Although the three FCC types showed similar
shape and size, they differed in intraparticle porosity and hence in tensile strength of the tablets.
Based on the results it was speculated that a higher pore volume of larger pores (pore diameter
of approximately 100 nm) resulted in tablets with higher tensile strength at compressive pressures
below 150MPa compared to particles with a lower pore volume of large pores. Above a compressive
pressure of 150MPa, the particles with a higher pore volume of very small pores (around 10 nm)
yielded in tablets with higher tensile strength compared to particles with lower pore volume of very
small pores. Based on these findings, it is recommended to use FCC S01 and S02 at compressive
pressures below 150MPa to produce tablets with highest possible tensile strength. At compressive
pressures above 150MPa it is recommended to use FCC S03 for the same purpose. With respect
to QbD, the intraparticle pore size distribution of FCC particles seems to be a critical material
attribute. A shift in the pore size distribution of FCC particles is assumed to be reflected in the
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tensile strength profile of the resulting tablets.
4.2 Granulation of FCC
To overcome the limitations of low bulk volume and poor flowability of FCC during direct com-
pression, the powder was granulated. Two different methods were used for granulation, namely
high shear granulation (wet granulation) and roller compaction (dry granulation).
Wet granulation
The tensile strength of tablets produced by high shear granulation was reduced in comparison to
tablets produced with FCC powder or roller compacted FCC granules. It was assumed that the
high shear forces in the mixer partially destroyed the stratum lamellae of FCC S02 and thus re-
duced the contact area, resulting in lower values for tensile strength.
In general, it was challenging to control the high-shear granulation process due to the fact that
FCC particles are porous, show an irregular shape, and the particles have a broad particle size dis-
tribution. Therefore, another set of experiments was performed with Fujicalin, a model substance
for spherical particles with a small particle size distribution. With these particles it was possible
to show that torque increase during wet granulation is a function of geometrical arrangements of
the spherical particles in the powder bed at increasing liquid content.
The findings with Fujicalin could not be directly transferred to FCC. In contrast to Fujicalin, FCC
particles are characterized by an irregular shape and the particle size distribution is broad. Al-
though Fujicalin has intraparticle pores, they do not absorb liquid. For FCC particles the situation
is different. It is expected, that during the wet granulation process of FCC, these intraparticle
pores are (partially) filled before the agglomeration process of the particles can take place. On one
hand filling of the pores needs more time for the process (first of all to fill the pores and later on
to dry them) and a higher amount of binder solution. On the other hand, the binder can plug
the pores and hence reduce the porosity. Furthermore, the attached binder on the surface of FCC
particles could prevent the particles to come together as close as possible that Van der Waals forces
can be built. Another point that should be kept in mind is the lamellar structure of FCC. At a
certain pressure / mechanical impact the lamellae could no longer withstand the impact and start
to collapse / interlock. The wet granulation of FCC has to be considered as a dynamic process,
where not only the shape of the particles is changing, but also the porosity and the saturation of
the pores. To develop a model that takes into consideration all of the mentioned points, remains
a challenge. For certain formulations, the above mentioned properties of FCC may be advanta-
geous. An example for such a formulation is a matrix system that is built by embedding the API
within the FCC particles. Collapsing and interlocking of particles could create a connected matrix
system. As discussed for the high-shear granulation, it is expected that fluidized-bed granulation
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will show similar problems with respect to plugged pores due to binder solution. In contrast to
the high densification during high shear granulation, it is expected that the granules obtained with
a fluidized bed process show marginal densification. Further investigations are necessary to prove
these assumptions.
Dry granulation
Roller compactors are equipped with a feeding system that allows processing of poor flowable
materials, such as FCC. With the help of the feeding screws, the powder is forced down to the
rolls. In case of FCC, the bulk volume is reduced dramatically during the roller compaction. This
densification takes mainly place in the nip-region, the area between the rolls where the reduction
in gap width occurs. To deliver enough powder to the nip region, the feeding screws have to rotate
at a high speed during roller compaction of FCC powder. For a scale-up process it is recommended
to consider a vacuum-deaeration system that results in a predensification of the FCC powder.
As already mentioned in the introduction (see "1.2.2 Granulation"), dry granulation is usually
connected to two main challenges, namely the loss of reworkability and the production of fines.
Granulated FCC powder showed improved powder properties at retained compactibility. Also the
intraparticle porosity was unaffected by the roller compaction process. These results indicate, that
the loss of reworkability is no issue for FCC. With respect to the production of fines, FCC and
Avicel formulations showed similar results. By modifying the surface of the rolls (knurled rolls),
the amount of fines can be further decreased, which solves the issues of fines.
If the porosity and high surface area of FCC particles have to be preserved during the granulation
process, dry granulation will be the process of choice. Based on the performed studies, roller
compaction is expected to be the most efficient way to produce granules with a good flowability
and high bulk density out of FCC. The obtained granules can be used for direct compression and
are suitable for scale-up processes.
4.3 Applicability of FCC as an ODT
In the context of this thesis, ODTs containing FCC were produced by direct compression. In
comparison to other excipients, FCC was able to overcome the limitation of insufficient hardness
during the production of highly porous ODTs. This innovative finding was related to the lamellar
structure of FCC. In addition, direct compressed ODTs made with FCC are much more time-
and cost efficient than ODTs produced by, for example, the lyophilization method. In comparison
to other direct compressed ODTs, in particular Risperidone oro, FCC showed considerably better
performance including higher tensile strength and faster disintegration time. To protect the valuable
findings, a patent was applied for the production of ODTs made of FCC [77].
For this thesis, ODTs were prepared manually by direct compaction of FCC powder with 3% of
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disintegrant. Figure 4.1 gives an overview of how FCC can be used in the future to produce ODTs.
The recommendations are based on the knowledge gained from FCC in the context of this thesis.
For the first approach (I), FCC is blended with the disintegrant and the API, followed by a direct
compaction of the powder mixture. This method is limited by the poor flowability and high bulk
density of FCC, which makes the automated industrial application impossible.
Approaches II-IV show how these limitations can be overcome by roller compaction. For the second
approach (II), FCC is blended with the disintegrant and the API and afterwards roller compacted.
This approach is especially recommended if the amount of API in the formulation is very high or
very low and hence could result in a segregation of the mixture. Subsequently the granules are
compacted into tablets. This approach is preferable due to the fact that the most uniform distri-
bution of the different components (API, FCC, and disintegrant) will be reached within a tablet,
compared to the other approaches.
A third approach (III) could be a "ready-to-mix" approach, depending on which granules consisting
of FCC and disintegrant can be produced in advance. A better mouth feel due to the disintegration
of the granules into smaller powder particles is the result of FCC granules containing disintegrant.
Later on these "ready-to-mix"-granules can be blended with an arbitrary API. For a successful
production it has to be ensured that the size of the granules and of the API are in the same range
in order to prevent segregation. If segregation is an issue, the second approach is more preferable.
In case of a high API load, an extragranular addition of disintegrant has to be considered. A high
API load could disconnect the infinite network of the disintegrant within the tablet, resulting in
an incomplete disintegration. It has to be determined experimentally if an extragranular addition
of disintegrant is favorable. In a final step, the powder blend consisting of granules and powder, is
finally compacted into tablets.
The fourth approach (IV) is only shown for completeness and does not have a practical relevance.
For this approach, FCC powder is roller compacted prior to blending it with the other components.
The FCC granules are blended with the disintegrant and the API and afterwards the mixture is
compacted into a tablet. Adding the disintegrant after the granulation step involves the risk of an
incomplete disintegration of the tablet and especially of the FCC granules. In this case, there is no
possibility for the disintegrant to form the infinite network through the tablet that is needed for a
complete disintegration. An incomplete disintegration does not only change the pharmacokinetic
properties of the formulation, but also results in larger particles on the tongue and hence a bad
mouth-feel of the formulation.
For scale-up and industrial production of ODTs made with FCC, a granulation step is necessary in
order to increase the flowability of FCC particles. Wet granulation is no option to produce granules
for an ODT formulation due to the fact that the disintegrant lost its property of swelling after
the first contact with water (in this case during the granulation). Instead, roller compaction is
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Figure 4.1: Four different approaches to produce ODTs containing FCC are shown. Approach
(I) is limited by the poor flowability and high bulk density of FCC powder. These limitations
were overcome by a roller compaction process (approaches II-IV). Most uniform distribution of the
individual components within a tablet is expected for the approach (II). For that reason, approach
(II) would be the most recommendable way to produce ODTs containing FCC. The approach (III) is
a "ready-to-mix" approach where FCC granules contain disintegrant to improve patient compliance
with a better mouth feel. Tablets prepared by approach (IV) bear the risk of incomplete tablet
disintegration and hence, changed pharmacokinetics and reduced patient compliance due to bad
mouth-feel.
the process of choice, due to the fact that high porosity and compactability are retained and the
properties of the disintegrant are preserved during the dry granulation process. In summary, it is
recommended to follow the second approach (II) shown in Figure 4.1 to produce ODTs made with
FCC. This approach offers the most uniform distribution of the different tablet components within
the tablet and hence guarantees a fast and continuous disintegration of the tablet.
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Chapter 5
Conclusion and Outlook
The characterization of co-processed FCC revealed a promising new pharmaceutical excipient with
a broad application spectrum. The mechanistic study showed that tablets with high tensile strength
and high porosity can be obtained even at low compressive pressures. In comparison to convention-
ally used excipients such as MCC, mannitol, or calcium carbonate, the attributes of FCC present
a striking success in the field of excipient research. The key factor for the outstanding performance
of FCC and its multifunctionality is the lamellar structure of the particle, which forms a porous
meshwork (intraparticle porosity), resulting in a high specific surface area. To overcome the limi-
tations of poor flowability and high bulk density of FCC powder during direct compression, FCC
powder was roller compacted (dry granulated). The granules obtained by roller compaction showed
excellent flowability and reduced bulk volume, whereas all the outstanding properties of the pow-
der, such as compactability and compressibility, were preserved. With the dry granulation process,
the new excipient was converted into a suitable form for scale-up processes on high-throughput
rotary tablet presses.
With the conventional disintegration test described in PhEur [9] it was not possible to measure
the disintegration time of ODTs containing FCC. For this purpose, a highly sensitive tensiometer-
based method was proposed. The new method did not only measure disintegration time, but also
kinetics of weight loss during tablet disintegration was measured.
Application outlook of FCC as a pharmaceutical excipient
FCC particles showed a porosity of approximately 70% (v/v) and a specific surface area of approx-
imately 60 m2/g. This huge empty space and surface within the particle can be used manifold.
Subsequently, three prospective application fields are highlighted.
Carrier : The unique structure of FCC with lamellae and thus high porosity makes the particles
interesting as a carrier. Preisig et al. [78] showed, that the intraparticle pores of FCC can be loaded
with APIs. The achieved drug load was 40% (w/w), in which the API was mainly deposited in
the stratum voids (outer part of intraparticle pores). Furthermore, Preisig et al. [78] compared
the drug release out of a drug-loaded FCC particle with the release out of a FCC-drug mixture.
They found that drug release of a poorly water-soluble drug was accelerated by loading it into FCC
particles. This effect has been explained by the fact that the API is distributed over a large specific
surface area that stands in direct contact to the dissolution media.
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Adsorbent for liquids: The high intraparticle porosity of FCC can not only be used as a drug de-
livery system, but also as an absorbent for various liquids. As already discussed in this thesis, the
water uptake into a FCC powder bed is remarkably fast. Amongst others, FCC particles could be
used instead of talc in powder formulations to treat weeping wounds. The capillary action provided
by the special alignment of the lamellae could dry the wound by absorbing the liquid into the FCC
particles.
Adsorbent for particles: FCC and active coal (charcoal) share the characteristic of having a high
specific surface area. Active coal shows an activated (modified) surface that allows binding toxins
in the intestinal tract. Therefore, active coal is indicated as an antidote after intoxication or to
treat acute diarrhea. Similar surface modifications as for active coal should be feasible for FCC in
order to bind on specific substances in the intestinal tract.
With respect to solid dosage forms, the applicability of FCC seems to be of particular interest for
formulations that are characterized by high porosity, high tensile strength, or both. Subsequently,
some examples of such formulations are provided.
ODTs: Conventional ODTs usually show a high porosity that is limited by low tensile strength
of the tablet. Excipients for ODT formulations are distinguished by two critical properties. The
first one, a disintegration time of a few seconds, is of pharmacological interest and improves the
compliance. The second, a high tensile strength of the tablet, is of interest with respect to packing
the tablet into a blister. A successful ODT formulation needs to have a high porosity that allows
the liquid to penetrate through the tablet within seconds and a high tensile strength that the end
product can be packed into a push-through blister. ODTs containing FCC were able to overcome
the limitation of insufficient hardness and showed a disintegration time of less than 10 seconds at
the same time. The high tensile strength of ODTs prepared from FCC allows producing ODTs
with break lines. This feature does not yet exist on the market due to insufficient hardness of direct
compressed ODTs. With respect to the requirements of the European Union that state a need for
age-related tablet formulations, FCC could facilitate the formulation work. With the introduction
of ODTs with break lines it could be possible that the dose of one tablet covers the need of different
age groups. As an example, parents of a one-year-old child could break the ODT in quarters and
dispense one of these pieces in the feeding bottle to the child. For a five-years-old, the parents
could administer three-fourths of the same dosage form by placing the tablet in the mouth of the
child. These findings of high tensile strength and high porosity could revolutionize the production
of ODTs in the future.
Floating tablets: The requirements for the excipient to produce ODTs and floating tablets are the
same, namely high porosity and at the same time high tensile strength. Eberle et al. showed that
the intraparticle porosity of FCC particles can be used to produce floating tablets. To achieve
floating behavior, the density of the tablet has to be smaller than the density of the gastric fluid.
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At the same time, the high specific surface area provides sufficient contact area between particles,
resulting in a mechanically robust formulation with high tensile strength of the tablets.
Effervescent tablets: A marginal effervescing effect was observed during the disintegration of ODTs
consisting of FCC. The principle of an effervescent tablet is based upon a chemical reaction. Effer-
vescing tablets often contain sodium bicarbonate and citric acid. After the tablet comes in contact
with water, carbon dioxide is released, resulting in an effervescing effect. Similar effect could be
achieved by mixing FCC with an acid, such as citric acid. In addition, a disintegrant could be
added to guarantee complete disintegration of the tablet. The advantage of using FCC to produce
effervescent tablets could be the capillary action that is provided by the unique structure of FCC,
resulting in a fast disintegration of the tablet. In addition, FCC particles can be used as a carrier
to increase the solubility of poorly water-soluble APIs by spreading the API over the high specific
surface area of FCC particles. FCC based effervescent tablets could be an alternative to conven-
tional effervescent tablets containing sodium. The use of sodium is controversially discussed due
to the fact that a study associated the use of sodium for effervescent tablets with cardiovascular
events [79].
Release-controller : If the challenge of drug loading into the core of FCC particles could be over-
come, FCC could be used to design the whole range of release profiles; from immediate release
to sustained release formulations. An ODT formulation is an example for an immediate release
formulation. A sustained release profile (repository-effect) could be achieved by loading the core
pores of the particles. Depending on the used API, the dissolution of the API out of the pores
could result in a sustained release profile. The two approaches could also be combined to obtain
a formulation with an initial boost of drug that is afterwards kept constant (steady-state) by sus-
tained drug release out of the inner FCC pores.
Ultra hard tablets: Crushing of sustained release formulations that results in an immediate drug
release is an approach commonly used by drug addicts. Amongst others, such abuses were observed
for opiate formulations. The company Grünenthal invented a tablet with a hardness over 500N
that can no longer be crushed especially for this purpose [80]. As it has already been shown in
this thesis, the compaction of FCC resulted in very hard tablets. The reason for this extraordinary
high hardness was the high surface area that provided innumerable contact points for strong bind-
ings. Therefore, FCC could be a promising basic excipient for the production of UHTs. While the
Grünenthal technology involves a cost- and time-intensive hot-melt extrusion process, FCC UHTs
are direct compactable. For that purpose, FCC granules can be mixed with other excipients, if
necessary, followed by a direct compaction process.
Cushioning agent: The production of a multiple unit pellet system (MUPS) is a critical process.
During the tableting process, the pellets are embedded within an excipient matrix. With the exist-
ing excipients on the market, the pressure during tableting has to be adjusted carefully in order to
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avoid breaking the pellets as a result of too high pressure. On the other hand, the tablet requires
a certain pressure in order to reach the required mechanical robustness. Finding the appropriate
pressure is a challenging task with conventional excipients. Based on the findings in this thesis,
FCC could overcome these limitations by acting as a cushioning agent. Even at low compres-
sive pressure, FCC formed tablets with high tensile strength due to the high specific surface area
available for binding. In addition, this could result in a higher load of pellets.
The near future of FCC - The way on the market
Based on the results of our group, FCC will be introduced into the market of pharmaceutical
excipients in the year 2015. At present, an industrial partner is setting up production facilities and
is preparing the registration. It is planned to register FCC under the brand name "Omyapharm"
as shown in Figure 5.1 [81]. Hopefully, FCC will find, due to its exceptional properties, widespread
use in the pharmaceutical industry in the years to come.
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